

Fig. 6. Effect of a single dose of PC-SOD on the development of DSS-induced colitis. PC-SOD was intravenously administered to mice once at the start of DSS treatment (day 0). Colitis was subsequently assessed, as described in the legend of Fig. 1. Values are mean  $\pm$  S.E.M. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

When we monitored the level of PC-SOD after this single-dose administration (12 kU/kg), we found that it dropped below detectable limits 72 (in serum) or 24 (in colonic tissues) h after the injection (Table 3).

We also examined the effect of oral administration (once daily) of PC-SOD. As shown in Fig. 7A, significant improvement in the DAI score was observed at most of the doses tested. The ameliorative effect of oral administration of PC-SOD was also observed in terms of colon shortening and colonic MPO activation (Fig. 7, B and C). This suggests that oral administration of PC-SOD, a regime that greatly improves the QOL of UC patients, is a viable clinical protocol

and is also clinically viable. We found that the level of PC-SOD in serum did not increase at any time points (6–48 h) after the oral administration of PC-SOD (48 kU/kg) (Table 4), suggesting that orally administered PC-SOD is not absorbed and reaches the intestinal mucosa directly. By employing an ELISA assay, we detected the PC-SOD in the colonic tissues 24 h after its oral administration (48 kU/kg) (Table 4). However, low doses (0.75–1.5 kU/kg) proved undetectable (data not shown).

## Discussion

The efficacy of PC-SOD for the treatment of UC patients has already been demonstrated by a phase II clinical study (Suzuki et al., 2008b). However, the mechanism of its action is not fully understood. Given that determining the underlying mechanism is important to advance the further development of this drug, in the present study, we examined the action of PC-SOD in an animal model of UC, DSS-induced colitis. Furthermore, because the current clinical protocol for

TABLE 3

Serum and colonic levels of PC-SOD

Mice were intravenously administered 12 kU/kg PC-SOD once on day 0 and treated with DSS for 3 days. Blood and colonic tissue samples were taken periodically. The levels of PC-SOD in the samples were determined by ELISA. Values are mean  $\pm$  S.E.M.

	15 min	24 h	48 h	72 h
Serum ( $\mu$ g/ml)	170 $\pm$ 5.7	2.3 $\pm$ 0.67	0.41 $\pm$ 0.12	<0.16
Tissue (ng/mg)	1.6 $\pm$ 0.69	<0.031	<0.031	<0.031




Fig. 7. Effect of oral administration of PC-SOD on development of DSS-induced colitis. PC-SOD was orally administered to mice once daily. Colitis was assessed, as described in the legend of Fig. 1. Values are mean  $\pm$  S.E.M. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

TABLE 4

Serum and colonic levels of PC-SOD

Mice were orally administered 48 kU/kg PC-SOD once and treated with DSS for 2 days. Blood and colonic tissue samples were taken periodically. The levels of PC-SOD in the samples were determined by ELISA. Values are mean  $\pm$  S.E.M.

	6 h	12 h	24 h	48 h
Serum ( $\mu\text{g/ml}$ )	<0.16	<0.16	<0.16	<0.16
Tissue ( $\text{ng/mg}$ )	<0.031	<0.031	$0.46 \pm 0.24$	<0.031

the administration of PC-SOD (once daily intravenous infusion for 4 weeks) does not provide patients with good QOL, we also tested other dosing regimens in our animal model.

The superior character of PC-SOD to U-SOD has been shown both in vitro (high cell membrane affinity) and in vivo (high stability in plasma). However, a direct comparison of their pharmacological activity has not been reported. In this study, we have demonstrated that the ameliorative effect of PC-SOD against DSS-induced colitis is more than 30 times higher than that of U-SOD. The higher stability in serum (Table 1) and higher activity for decreasing superoxide anion (Fig. 3) of PC-SOD could contribute to this effect. Analysis of

intestinal ROS level in vivo is difficult; thus, the decrease in the level of ROS by PC-SOD has not been directly shown. In this study, we have demonstrated this by use of radical spin adduct ESR spectrum analysis. This analysis should also be useful for detecting the alteration in the intestinal level of ROS associated with various other diseases and for evaluation of drugs for the treatment of such conditions.

The bell-shaped dose-response profile of PC-SOD is of clinical concern because this may reflect side effects of the drug. In this study, we have revealed that the efficacy of higher doses of PC-SOD is restored by simultaneous administration of catalase that converts hydrogen peroxide to water and oxygen. Furthermore, we have directly determined the colonic level of hydrogen peroxide and found that low doses of PC-SOD suppress the DSS-induced increase in the intestinal level of hydrogen peroxide and that simultaneous administration of catalase with high doses of PC-SOD but not the PC-SOD alone produces a similar effect. These results suggest that the ineffectiveness of high doses of PC-SOD on DSS-induced colitis is caused by accumulation of hydrogen peroxide. Although catalase is abundant, recent studies have

suggested that its activity fluctuates during the development of colitis (Kruiderier et al., 2003b,c; Mahgoub et al., 2003). This may affect the clinical efficacy of PC-SOD, and individual examination of catalase activity before the administration of the drug may result in safer and more effective treatment. Hydrogen peroxide is not itself a major cause of ROS-mediated cell damage, but it does react with  $Fe^{2+}$  to produce a potent hydroxy radical according to the Fenton reaction (Mao et al., 1993). Furthermore, it has been reported that among various ROS, hydrogen peroxide is the most potent activator of NF- $\kappa$ B, a strong inducer of inflammation through induction of proinflammatory cytokines, especially TNF- $\alpha$  (Schmidt et al., 1995; Marikovsky et al., 2003) and that NF- $\kappa$ B plays an important role in intestinal colitis (Schreiber et al., 1998; Herfarth et al., 2000). Here, we have shown that activation of NF- $\kappa$ B, the mRNA expression of *Tnf- $\alpha$* , and the serum level of TNF- $\alpha$  are induced when the colonic level of hydrogen peroxide increases, suggesting that hydrogen peroxide damages the intestinal mucosa both through induction of inflammation via activation of NF- $\kappa$ B and through direct cell damage mediated in conjunction with hydroxy radical formation.

In the present study, we have also demonstrated that administration of a single high dose of PC-SOD at the start of DSS treatment significantly suppresses colitis. The serum or intestinal level of PC-SOD dropped below detectable limits 72 or 24 h, respectively, after the injection (Table 3), suggesting that the existence of PC-SOD in the early stages of development of colitis is important for its ameliorative effect. The present clinical protocol for PC-SOD administration to UC patients enforces their hospitalization. Our results suggest that intermittent (for example, once weekly) administration of PC-SOD, thereby allowing ambulatory administration of the drug, may be an effective and preferable treatment for UC patients.

We also found that oral administration of PC-SOD (0.75–48 kU/kg) significantly suppressed DSS-induced colitis. The serum level of PC-SOD did not increase after the oral administration, suggesting that orally administered PC-SOD is not absorbed but reaches the colonic mucosa directly. However, based on ELISA assay, we only detected PC-SOD in colonic tissues after administration of the highest dose tested (48 kU/kg), the tissue level being similar to that obtained after intravenous administration of a 3 kU/kg dose (Table 1). Thus, it seems that a very small amount of PC-SOD (under the limit of detection) is effective when administered orally. The distribution of PC-SOD at the intestine may differ depending on the route of administration, and this may contribute to the higher specific activity of PC-SOD after oral treatment. The fact that a bell-shaped dose-response profile was not observed upon oral administration of PC-SOD (Fig. 7) supports this idea. On the other hand, it is also possible that PC-SOD is modified at the gastric and intestinal mucosa in such a way that it is not recognized by the ELISA assay, although its activity is maintained. If oral administration of PC-SOD is applied clinically, it should greatly improve the QOL of patients treated with the drug. We used human SOD, not mouse protein, for the examination of the effect of oral administration of PC-SOD on DSS-induced colitis in mice. Human SOD may modify the mucosal immunological reaction in mice, and this modification may stimulate the beneficial effect of PC-SOD against colitis in mice. In this case,

oral administration of PC-SOD may not give beneficial effects for human.

Glucocorticoids, 5-aminosalicylic acid, and immunosuppressive drugs are currently used for the clinical treatment of IBD (Podolsky, 2002; Baumgart and Sandborn, 2007). Although some new types of drugs, such as infliximab, have been developed recently, a number of clinical problems, such as side effects, have yet to be addressed (Keane et al., 2001; Bongartz et al., 2006; Baumgart and Sandborn, 2007). Thus, IBD remains a disease for which the development of new types of drugs remains therapeutically important. Clinical studies have suggested that PC-SOD is a relatively safe drug. Furthermore, it has a mechanism of action that is different from that of other currently used drugs and those that are under clinical development. Thus, PC-SOD remains a therapeutically beneficial option for UC patients, either through a single administration or in combination with other types of drugs.

ROS play an important role in the progression of not only IBD but also various other diseases, such as focal cerebral ischemic injury, pulmonary fibrosis, chemotherapy-induced cardiotoxicity, and motor dysfunction after spinal cord injury. Therefore, it is worth noting in conclusion that a number of animal studies have suggested that PC-SOD is also effective in the treatment of these conditions (Tamagawa et al., 2000; Chikawa et al., 2001; Nakajima et al., 2001; den Hartog et al., 2004; Tsubokawa et al., 2007). Thus, the results obtained in this paper should provide useful evidence when considering the most appropriate clinical protocol for therapeutic administration of PC-SOD against these diseases.

## References

- Baumgart DC and Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. *Lancet* 369:1641–1657.
- Bongartz F, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, and Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 295:2275–2285.
- Broeyer FJ, van Aken BE, Suzuki J, Kemme MJ, Schoemaker HC, Cohen AF, Mizushima Y, and Burggraaf J (2008) The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man. *Br J Clin Pharmacol* 65:22–29.
- Chikawa T, Ikata T, Katoh S, Harauda Y, Kogure K, and Fukuzawa K (2001) Preventive effects of lecithinized superoxide dismutase and methylprednisolone on spinal cord injury in rats: transcriptional regulation of inflammatory and neurotrophic genes. *J Neurotrauma* 18:93–103.
- Cuzscores S (2003) Emerging biotherapies for inflammatory bowel disease. *Expert Opin Emerg Drugs* 8:339–347.
- den Hartog GJ, Haenen GR, Boven E, van der Vijgh WJ, and Bast A (2004) Lecithinized copper,zinc-superoxide dismutase as a protector against doxorubicin-induced cardiotoxicity in mice. *Toxicol Appl Pharmacol* 194:180–188.
- Greenwald RA (1990) Superoxide dismutase and catalase as therapeutic agents for human diseases: a critical review. *Free Radic Biol Med* 8:201–209.
- Herfarth H, Brand K, Rath HC, Rogler G, Schölmerich J, and Falk W (2000) Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. *Clin Exp Immunol* 120: 59–65.
- Hori Y, Hoshino J, Yamazaki C, Sekiguchi T, Miyauchi S, Mizuno S, and Horie K (1997) Effect of lecithinized-superoxide dismutase on the rat colitis model induced by dextran sulfate sodium. *Jpn J Pharmacol* 74:99–103.
- Igarashi R, Hoshino J, Ochiai A, Morizawa Y, and Mizushima Y (1994) Lecithinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity. *J Pharmacol Exp Ther* 271:1672–1677.
- Igarashi R, Hoshino J, Takenaga M, Kawai S, Morizawa Y, Yasuda A, Otani M, and Mizushima Y (1992) Lecithinization of superoxide dismutase potentiates its protective effect against Forsman antiserum-induced elevation in guinea pig airway resistance. *J Pharmacol Exp Ther* 262:1214–1219.
- Institute of Laboratory Animal Resources (1996) *Guide for the Care and Use of Laboratory Animals*, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
- Karakawa T, Sato K, Muramoto Y, Mitani Y, Kitamado M, Iwanaga T, Nabeshima T, Maruyama K, Nakagawa K, Ishida K, et al. (2008) Applicability of new spin trap agent, 2-diphenylphosphinoyl-2-methyl-3,4-dihydro-2H-pyrrole N-oxide, in biological system. *Biochem Biophys Res Commun* 370:93–97.
- Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD,

- Siegel JN, and Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* **345**:1098-1104.
- Keshavarzian A, Morgan G, Sedghi S, Gordon JH, and Doria M (1990) Role of reactive oxygen metabolites in experimental colitis. *Gut* **31**:786-790.
- Kruiderien L, Kuiper I, van Duijn W, Marklund SL, van Hogezand RA, Lamers CB, and Verspaget HW (2003a) Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. *J Pathol* **201**:7-16.
- Kruiderien L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, and Verspaget HW (2003b) Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. *J Pathol* **201**:17-27.
- Kruiderien L, van Meeteren ME, Kuiper I, Jaarsma D, Lamers CB, Zijlstra FJ, and Verspaget HW (2003c) Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. *Free Radic Biol Med* **34**:753-765.
- Kruiderien L and Verspaget HW (2002) Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? *Aliment Pharmacol Ther* **16**:1997-2015.
- Mahgoub AA, El-Medany AA, Hager HH, Mustafa AA, and El-Sabah DM (2003) Evaluating the prophylactic potential of zafirlucast against the toxic effects of acetic acid on the rat colon. *Toxicol Lett* **145**:79-87.
- Mao GD, Thomas PD, Lopuschuk GD, and Poznansky MJ (1993) Superoxide dismutase (SOD)-catalase conjugates: role of hydrogen peroxide and the Fenton reaction in SOD toxicity. *J Biol Chem* **268**:416-420.
- Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, and Mahler O (2003) Cu/Zn superoxide dismutase plays important role in immune response. *J Immunol* **170**:2993-3001.
- Mima S, Tsutsuami S, Ushijima H, Takeda M, Fukuda I, Yokomizo K, Suzuki K, Sano K, Nakanishi T, Tomisato W, et al. (2005) Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. *Cancer Res* **65**:1868-1876.
- Muranaka H, Suga M, Sato K, Nakagawa K, Akaike T, Okamoto T, Maeda H, and Ando M (1997) Superoxide scavenging activity of erythromycin-iron complex. *Biochem Biophys Res Commun* **232**:183-187.
- Nakajima H, Hangaishi M, Ishizaka N, Taguchi J, Igarashi R, Mizushima Y, Nagai R, and Ohno M (2001) Lecithinized copper, zinc-superoxide dismutase ameliorates ischemia-induced myocardial damage. *Life Sci* **69**:935-944.
- Podolsky DK (2002) Inflammatory bowel disease. *N Engl J Med* **347**:417-429.
- Salimuddin, Nagasaki A, Gotoh T, Isobe H, and Mori M (1999) Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide. *Am J Physiol* **277**:E110-E117.
- Sato K, Akaike T, Kohno M, Ando M, and Maeda H (1992) Hydroxyl radical production by H<sub>2</sub>O<sub>2</sub> plus Cu,Zn-superoxide dismutase reflects the activity of free copper released from the oxidatively damaged enzyme. *J Biol Chem* **267**:25371-25377.
- Sato K, Kadiiska MB, Ghio AJ, Corbett J, Fann YC, Holland SM, Thurman RG, and Mason RP (2002) In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS. *FASEB J* **16**:1713-1720.
- Schmidt KN, Amstad P, Cerutti P, and Baeuerle PA (1995) The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. *Chem Biol* **2**:13-22.
- Schreiber S, Nikolaus S, and Hampel J (1998) Activation of nuclear factor kappa B in inflammatory bowel disease. *Gut* **42**:477-484.
- Segui J, Gironella M, Sans M, Granell S, Gil F, Gimeno M, Coronel P, Piqué JM, and Panés J (2004) Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. *J Leukoc Biol* **76**:537-544.
- Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, and Rampton DS (1992) Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. *Gastroenterology* **103**:186-196.
- Suzuki J, Broeyer F, Cohen A, Takebe M, Burggraaf J, and Mizushima Y (2008a) Pharmacokinetics of PC-SOD, a lecithinized recombinant superoxide dismutase, after single- and multiple-dose administration to healthy Japanese and Caucasian volunteers. *J Clin Pharmacol* **48**:184-192.
- Suzuki Y, Matsumoto T, Okamoto S, and Hibi T (2008b) A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. *Colorectal Dis* **10**:931-934.
- Tamagawa K, Tsooka Y, Maeda A, Hiyama K, Ishioka S, and Yamakido M (2000) Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. *Am J Respir Crit Care Med* **161**:1279-1284.
- Tanaka K, Namba T, Arai Y, Fujimoto M, Adachi H, Sobue G, Takeuchi K, Nakai A, and Mizushima T (2007) Genetic evidence for a protective role for heat shock factor 1 and heat shock protein 70 against Colitis. *J Biol Chem* **282**:23240-23252.
- Tsao C, Greene P, Odland B, and Brater DC (1991) Pharmacokinetics of recombinant human superoxide dismutase in healthy volunteers. *Clin Pharmacol Ther* **50**:713-720.
- Tsubokawa T, Jadhav V, Solaroglu I, Shiokawa Y, Konishi Y, and Zhang JH (2007) Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. *Stroke* **38**:1057-1062.
- Yasui K and Baba A (2006) Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation. *Inflamm Res* **55**:359-363.

**Address correspondence to:** Dr. Tohru Mizushima, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan. E-mail: mizu@gpo.kumamoto-u.ac.jp

## ATP drives lamina propria T<sub>H</sub>17 cell differentiation

Koji Atarashi<sup>1\*</sup>, Junichi Nishimura<sup>1\*</sup>, Tatsuichiro Shima<sup>2</sup>, Yoshinori Umesaki<sup>2</sup>, Masahiro Yamamoto<sup>1,3</sup>, Masaharu Onoue<sup>2</sup>, Hideo Yagita<sup>4</sup>, Naoto Ishii<sup>5</sup>, Richard Evans<sup>6</sup>, Kenya Honda<sup>1,3</sup> & Kiyoshi Takeda<sup>1,3</sup>

Interleukin (IL)-17-producing CD4<sup>+</sup> T lymphocytes (T<sub>H</sub>17 cells) constitute a subset of T-helper cells involved in host defence and several immune disorders<sup>1,2</sup>. An intriguing feature of T<sub>H</sub>17 cells is their selective and constitutive presence in the intestinal lamina propria<sup>3</sup>. Here we show that adenosine 5'-triphosphate (ATP) that can be derived from commensal bacteria activates a unique subset of lamina propria cells, CD70<sup>high</sup>CD11c<sup>low</sup> cells, leading to the differentiation of T<sub>H</sub>17 cells. Germ-free mice exhibit much lower concentrations of luminal ATP, accompanied by fewer lamina propria T<sub>H</sub>17 cells, compared to specific-pathogen-free mice. Systemic or rectal administration of ATP into these germ-free mice results in a marked increase in the number of lamina propria T<sub>H</sub>17 cells. A CD70<sup>high</sup>CD11c<sup>low</sup> subset of the lamina propria cells expresses T<sub>H</sub>17-prone molecules, such as IL-6, IL-23p19 and transforming-growth-factor- $\beta$ -activating integrin- $\alpha$ V and - $\beta$ 8, in response to ATP stimulation, and preferentially induces T<sub>H</sub>17 differentiation of co-cultured naive CD4<sup>+</sup> T cells. The critical role of ATP is further underscored by the observation that administration of ATP exacerbates a T-cell-mediated colitis model with enhanced T<sub>H</sub>17 differentiation. These observations highlight the importance of commensal bacteria and ATP for T<sub>H</sub>17 differentiation in health and disease, and offer an explanation of why T<sub>H</sub>17 cells specifically present in the intestinal lamina propria.

The intestinal mucosa has a unique and complicated immune system composed of a variety of cell populations. Among these, T<sub>H</sub>17 cells, a subset of CD4<sup>+</sup> T cells characterized by their STAT3-dependent expression of ROR $\gamma$ t (encoded by *Rorc*) and production of IL-17, IL-22 and IL-21, control a variety of bacterial and fungal infections at mucosal surfaces<sup>1,2</sup>. Importantly, aberrant T<sub>H</sub>17 responses have been implicated in the pathogenesis of inflammatory bowel diseases<sup>4</sup>. The development of T<sub>H</sub>17 cells has been shown to be controlled by the local cytokine milieu, including IL-6, transforming growth factor- $\beta$  (TGF- $\beta$ ) and IL-23 (refs 1, 2, 7, 9–12). However, the mechanism of T<sub>H</sub>17 development in the intestine is as yet not fully understood.

IL-17-expressing cells constitute a considerable proportion of CD4<sup>+</sup> cells in the intestinal lamina propria, even in healthy mice kept under specific-pathogen-free (SPF) conditions (Supplementary Fig. 1a and ref. 3). The colonic lamina propria CD4<sup>+</sup> cells also express messenger RNAs for IL-17, IL-17F and ROR $\gamma$ t, representing the hallmarks of T<sub>H</sub>17 cells (Supplementary Fig. 1b). The number of these 'naturally occurring' T<sub>H</sub>17 cells in the colonic lamina propria increases with age (Supplementary Fig. 1c). Although interferon (IFN)- $\gamma$ -positive CD4<sup>+</sup> cells are similarly observed in the lamina propria and spleen, IL-17-producing cells are rarely observed in the spleen, mesenteric lymph node (MLN) or Peyer's patches (Supplementary Fig. 1a and ref. 3). Furthermore, the lamina propria

IL-17-producing CD4<sup>+</sup> cells were normally observed in Peyer's patch- and colonic-patch-null mice<sup>11</sup> (Supplementary Fig. 2). These observations suggest that a specific environment in the lamina propria supports the generation of T<sub>H</sub>17 cells *in situ*.

To investigate whether intestinal commensal bacteria are responsible for the generation of lamina propria T<sub>H</sub>17 cells, we evaluated the numbers of T<sub>H</sub>17 cells in germ-free mice. Although the numbers of colonic lamina propria CD4<sup>+</sup> cells were not significantly changed (Supplementary Fig. 3a), the numbers of IL-17-positive CD4<sup>+</sup> cells were greatly reduced in the large intestines of germ-free mice compared to those in SPF mice (Fig. 1a, b and Supplementary Fig. 3b). Consistent with previous reports<sup>11</sup>, the germ-free mice also exhibited severe reductions in their faecal IgA levels (Supplementary Fig. 3c), demonstrating that commensal bacteria contribute to the provision of a particular environment for lamina propria T<sub>H</sub>17 cells as well as IgA-producing cells. To examine the role of commensal bacteria further, we treated SPF mice with a combination of vancomycin and metronidazole by oral administration, and analysed lamina propria T<sub>H</sub>17 cells. The vancomycin- and metronidazole-treated mice showed marked reductions in their faecal IgA levels and their numbers of IL-17-producing CD4<sup>+</sup> cells (Supplementary Fig. 4a–c).

To assess the molecular basis for the commensal-bacteria-driven T<sub>H</sub>17 differentiation, we examined the contribution of Toll-like receptor (TLR) signalling using *Myd88*<sup>-/-</sup>*Trif*<sup>-/-</sup> mice, which lack all TLR signalling. There was no detectable difference in the numbers of lamina propria IL-17-producing CD4<sup>+</sup> cells between control and mutant animals (Fig. 1c, d and Supplementary Fig. 3d), indicating that the development of lamina propria T<sub>H</sub>17 cells is independent of TLR signalling. It is worth noting that *Myd88*<sup>-/-</sup>*Trif*<sup>-/-</sup> mice showed impaired secretion of IgA in their faecal pellets (Supplementary Fig. 3e), indicating that the development of intestinal T<sub>H</sub>17 cells and IgA-producing cells are both dependent on microflora, but are regulated by different mechanisms.

ATP has recently been shown to modulate immune cell functions by means of activation of the ATP sensors, P2X and P2Y receptors<sup>13–15</sup>. In addition, bacteria have been shown to generate and secrete large amounts of ATP<sup>16</sup>. Indeed, ATP concentrations in faecal samples without bacterial lysis were much higher in SPF mice than in germ-free mice (Fig. 1e). Consistent with this result, ATP concentrations were reduced in faecal samples from SPF mice treated with vancomycin and metronidazole (Supplementary Fig. 4d). Furthermore, high ATP concentration was detected in the supernatant of *in vitro* cultured intestinal commensal bacteria derived from faeces of SPF mice (Supplementary Fig. 5). Therefore, although there might be other cellular sources of ATP such as dead epithelial cells, commensal bacteria may be a major source of intestinal luminal ATP. Interestingly, the faecal ATP concentrations were not reduced in

<sup>1</sup>Laboratory of Immune Regulation, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. <sup>2</sup>Yakult Central Institute for Microbiological Research, Yaho 1796, Kunitachi, Tokyo 186-8650, Japan. <sup>3</sup>WPI Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan. <sup>4</sup>Department of Immunology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. <sup>5</sup>Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, 2-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. <sup>6</sup>Department of Cell Physiology and Pharmacology, Henry Wellcome Building 2/55b, University of Leicester, Leicester LE1 9HN, UK.


\*These authors contributed equally to this work.

*Myd88*<sup>-/-</sup>*Trif*<sup>-/-</sup> mice (Fig. 1f). These results prompted us to examine the contribution of ATP to the generation of intestinal  $T_H17$  cells. To this end, we treated germ-free mice with a non-hydrolysable ATP analogue, ATP $\gamma$ S (ref. 15), by intraperitoneal or rectal administration, and analysed the numbers of lamina propria IL-17-producing cells. The numbers of IL-17-producing CD4<sup>+</sup> cells were markedly increased in the ATP $\gamma$ S-treated germ-free mice (Fig. 1g–i). In contrast, ATP injection affected neither the numbers of IFN- $\gamma$ -producing CD4<sup>+</sup> cells (Fig. 1g, h) nor faecal IgA levels (Supplementary Fig. 3f). To assess further the possible involvement of ATP in  $T_H17$  differentiation, we treated SPF mice with an ATP-hydrolysing enzyme, apyrase, or with an antagonist of P2X receptors, 2',3'-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP)<sup>15</sup>. In the apyrase- or TNP-ATP-treated mice, the numbers of IL-17-producing lamina propria CD4<sup>+</sup> cells were significantly reduced (Fig. 1j, k), suggesting the key role of ATP in the generation of intestinal  $T_H17$  cells.

Accumulating evidence suggests that lamina propria CD11c<sup>+</sup> antigen-presenting cells directly sample the luminal contents and activate T cells<sup>20,21</sup>. Indeed, the induction of mRNAs for IL-6 (encoded by *Il6*), IL-23p19 (*Il23a*) and integrin- $\alpha$ V (*Itgav*) and - $\beta$ 8 (*Itgb8*) was observed in lamina propria CD11c<sup>+</sup> cells, but not in CD11c<sup>-</sup> cells or


epithelial cells, harvested from ATP $\gamma$ S-treated germ-free mice (Supplementary Fig. 6). Integrin- $\alpha$ V and - $\beta$ 8 are known to be involved in the activation of latent complexes of TGF- $\beta$ <sup>22</sup>. Therefore, we assumed that ATP promotes  $T_H17$  differentiation by means of stimulation of lamina propria CD11c<sup>+</sup> cells. Accordingly, we next co-cultured lamina propria CD11c<sup>+</sup> cells with splenic naive CD4<sup>+</sup>CD62L<sup>+</sup> T cells in the presence of a culture supernatant of intestinal commensal bacteria, which contained a high amount of ATP (Supplementary Fig. 5). Addition of this supernatant markedly enhanced differentiation of IL-17-expressing cells, but not of IFN- $\gamma$ -expressing cells (Fig. 2a). This  $T_H17$  differentiation was severely inhibited by the presence of apyrase. In contrast, a culture supernatant from *Salmonella typhimurium* showed a lower concentration of ATP and weaker ability to induce  $T_H17$  differentiation (Fig. 2a and Supplementary Fig. 5). Notably, the culture supernatant from *S. typhimurium* potentially induced  $T_H17$  differentiation, but this was not inhibited by apyrase (Fig. 2a).

To assess whether ATP was sufficient to induce  $T_H17$  differentiation, we co-cultured lamina propria or splenic CD11c<sup>+</sup> cells with splenic naive CD4<sup>+</sup> cells in the presence of ATP $\gamma$ S. The expression levels of *Il17a*, *Il17f*, *Il21* and *Il22*, but not *Ifng*, were markedly increased in CD4<sup>+</sup> cells cultured with lamina propria CD11c<sup>+</sup> cells in the presence of ATP $\gamma$ S (Fig. 2b and Supplementary Fig. 7a). The  $T_H17$  differentiation was also enhanced by another non-hydrolysable form of ATP,  $\alpha$ , $\beta$ -methylene-ATP ( $\alpha\beta$ -ATP), and weakly enhanced by 2,3-O-(4-benzoylbenzoyl)-ATP (Bz-ATP)<sup>15</sup> (Supplementary Fig. 7b). *Myd88*<sup>-/-</sup>*Trif*<sup>-/-</sup> CD11c<sup>+</sup> cells and control cells exerted a similar effect on CD4<sup>+</sup> cells, ruling out the possibility of endotoxin contamination (Supplementary Fig. 7c). The effect by ATP $\gamma$ S or  $\alpha\beta$ -ATP on  $T_H17$  differentiation was inhibited by pharmacological blockade of P2X and P2Y receptors using suramin, or a combination of TNP-ATP and brilliant blue G<sup>15</sup> (Supplementary Fig. 8). Importantly, these inhibitors had no effect



**Figure 1** | Administration of ATP leads to a marked increase in lamina propria  $T_H17$  cells in otherwise  $T_H17$ -lacking germ-free mice.


**a–d**, Representative FACS dot plots gated on colonic lamina propria CD4<sup>+</sup> cells in the indicated mice are shown in **a** and **c**, and the percentages of IL-17-producing CD4<sup>+</sup> cells of individual mice are shown in **b** and **d**. GF, germ free. **e, f**, Faecal ATP levels (pmol per g faeces) in the indicated individual mice. **g–k**, Germ-free mice (ICR) were daily injected intraperitoneally (i.p.) or rectally with medium or ATP $\gamma$ S (**g–i**). SPF mice were i.p. injected with PBS or apyrase, or with TNP-ATP (**j, k**). All mice were processed for FACS as in **a–d**. All experiments were performed more than twice with similar results. Horizontal bars indicate the means. \*\* $P < 0.01$ , \* $P < 0.05$ ; NS, not significant.



**Figure 2** | ATP induces differentiation of naive CD4<sup>+</sup> T cells into  $T_H17$  cells.

**a**, Splenic naive CD4<sup>+</sup> T cells were co-cultured with colonic lamina propria CD11c<sup>+</sup> with 20% conditioned medium from cultures of intestinal commensal bacteria (ICB) or *S. typhimurium* (*S. typhi*) in the presence or absence of apyrase. After 4 days, T cells were collected, restimulated and assayed for expression of *Il17* and *Ifng* by rRT-PCR. **b, c**, rRT-PCR analyses for the indicated genes of splenic naive CD4<sup>+</sup> T cells cultured with colonic lamina propria (LP) or splenic CD11c<sup>+</sup> cells in the presence of ATP $\gamma$ S (**b**) with or without anti-IL-6, anti-TGF- $\beta$  or their combination (**c**). **d**, rRT-PCR analyses for the indicated genes of splenic naive CD4<sup>+</sup> T cells from *Stat3*<sup>+/f</sup> Lck-Cre or *Stat3*<sup>+/f</sup> mice cultured with colonic LP CD11c<sup>+</sup> cells in the presence of ATP $\gamma$ S or  $\alpha\beta$ -ATP. Error bars, s.d. \* $P < 0.05$ , \*\* $P < 0.01$ . Representative results are shown from one of two to five independent experiments.

on, or slightly enhanced,  $T_H17$  cell differentiation. Although there might be other molecules affected by the ATP analogues and inhibitors we used, our results support the notion that the specific effect of ATP on  $T_H17$  differentiation was mediated by P2X and P2Y receptors. The ATP-mediated enhancement of  $T_H17$  differentiation was inhibited by anti-IL-6 or anti-TGF- $\beta$  antibodies, and more severely inhibited by the combination of both antibodies (Fig. 2c). Consistent with this result,  $Il6^{-/-}$  CD11c $^{+}$  cells failed to induce the differentiation of IL-17-producing cells in response to ATP (Supplementary Fig. 7d). In addition, no effects of ATP on the differentiation of cells expressing *Il17a* and *Rorc* were observed for CD4 $^{+}$  cells from *Stat3<sup>fl/fl</sup>* mice crossed onto Lck-Cre mice (*Stat3<sup>fl/fl</sup>* Lck-Cre mice), in which the Cre transgene is under the control of the *Lck* promoter<sup>23</sup> (Fig. 2d). These results suggest that ATP stimulates lamina propria CD11c $^{+}$



**Figure 3** | A unique subset of lamina propria CD11c $^{+}$  cells express P2X and P2Y receptors. **a**, Flow cytometry of cells isolated from the colonic lamina propria, spleen or MLN. Numbers indicate the percentages of CD70 $^{low}$ CD11c $^{high}$  cells (R1) or CD70 $^{high}$ CD11c $^{low}$  cells (R2). **b**, rRT-PCR analyses for P2X and P2Y receptors in R1, R2 or splenic CD11c $^{+}$  cells. **c**, The sorted R1 and R2 cells were stimulated with  $\alpha\beta$ -ATP for 3 h and assayed for expression of the indicated genes. **d**, The sorted R1 and R2 cells were co-cultured with splenic naive CD4 $^{+}$  T cells with ATP $\gamma$ S or  $\alpha\beta$ -ATP for 4 days. The levels of indicated mRNAs in the co-cultured T cells were analysed by rRT-PCR. Data are presented as means  $\pm$  s.d. of triplicate determinations. All experiments were performed more than three times with similar results.  $^{**}P < 0.01$ .

cells to produce IL-6 and TGF- $\beta$ , thereby promoting the  $T_H17$  differentiation by activation of STAT3 in CD4 $^{+}$  cells.

The heterogeneity of lamina propria CD11c $^{+}$  cells has been addressed in a number of studies<sup>24</sup>. Therefore, we investigated which subsets of lamina propria CD11c $^{+}$  cells mediate  $T_H17$  development. Flow cytometry analyses led to the identification of two major CD11c $^{+}$  populations in the colonic lamina propria: CD70 $^{low}$ CD11c $^{high}$  cells (termed R1) and CD70 $^{high}$ CD11c $^{low}$  cells (termed R2; Fig. 3a). The R2 population comprised a unique subset present in the lamina propria (Fig. 3a). This subset was positive for myeloid lineage cell markers, such as F4/80 and CD11b, and exhibited immune-activating properties, as was evident from their high expression of CD70 and CD80, but was negative for the immunosuppressive marker CD103 (Supplementary Fig. 9a and refs 25 and 26). R2 cells also expressed CX3CR1; thus, this population seems to be a part of the previously described CX3CR1 $^{+}$ CD11b $^{high}$ CD11c $^{low}$   $T_H17$ -inducing subset<sup>26</sup> (Supplementary Fig. 9a–c). R2 cells were observed in the lamina propria of germ-free mice or Peyer's-patch and colonic-patch-null mice (Supplementary Fig. 11a, b), suggesting that this subset of cells develop by means of microflora- and Peyer's-patch-/colonic-patch-independent mechanisms. Because treatment with a blocking antibody for CD70 or deficiency of CD27, a receptor for CD70 (ref. 27), did not influence the number of lamina propria  $T_H17$  cells (data not shown), CD70 itself is dispensable for  $T_H17$  differentiation.

Next, we sorted R1 or R2 cells (Supplementary Fig. 10) and examined their expression of P2X and P2Y receptors by real-time polymerase chain reaction with reverse transcription (rRT-PCR). R2 cells expressed higher levels of mRNA for P2X1, P2X2, P2X4, P2X7, P2Y1, P2Y2, P2Y6 and P2Y12 receptors than R1 cells or splenic CD11c $^{+}$  cells (Fig. 3b). Furthermore, R2 cells expressed *Il6*, *Il23a*, *Itgav* and *Itgb8* in response to ATP (Fig. 3c). In addition, on ATP stimulation, R2 cells expressed tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), which has been implicated in  $T_H17$  responses in humans<sup>28</sup>. R2 cells, but not R1 cells, efficiently induced the differentiation of co-cultured naive CD4 $^{+}$ CD62L $^{+}$  T cells into IL-17-expressing cells, and this effect was markedly enhanced by the presence of ATP (Fig. 3d). Although the R2 population also induced T cells to differentiate into IFN- $\gamma$ -positive cells, this effect was not enhanced by ATP $\gamma$ S (Fig. 3d). In this experimental setting, IL-4-expressing cells were also induced, but this effect was more remarkable in co-cultures with R1 cells, suggesting that R1 and R2 cells carry out distinct missions with each other. R2 cells present in germ-free mice expressed low levels of *Il6* and *Itgb8*, and showed lower ability to induce  $T_H17$  differentiation of co-cultured naive CD4 $^{+}$  T cells (Supplementary Fig. 11c, d); however, by the addition of ATP $\gamma$ S, R2 cells from germ-free mice efficiently enhanced the  $T_H17$  differentiation (Supplementary Fig. 11d). These results all support the hypothesis that commensal-bacteria-derived ATP is responsible for the activation of R2 cells and subsequent development of  $T_H17$  cells.

To extend our understanding of the role of ATP in the differentiation of  $T_H17$  cells, we examined the effects of ATP on intestinal inflammation. We adoptively transferred naive wild-type CD4 $^{+}$  T cells into severe combined immunodeficient (SCID) mice<sup>29</sup>, treated these mice with  $\alpha\beta$ -ATP or medium, and monitored the severity of their colitis. Although both groups developed colitis, treatment with  $\alpha\beta$ -ATP exacerbated the symptoms of the disease, including diarrhoea and weight loss (Fig. 4a, Supplementary Fig. 12a and data not shown). Extensive oedema was prominent in the colon of  $\alpha\beta$ -ATP-treated SCID mice (Supplementary Fig. 12b). Histological analyses revealed that inflammatory cell infiltration, epithelial hyperplasia and loss of goblet cells were more evident in the colon of  $\alpha\beta$ -ATP-treated SCID mice (Fig. 4b). Notably, in contrast to a lack of considerable effect on IFN- $\gamma$ -positive cells, the number of IL-17-positive CD4 $^{+}$  cells was significantly increased in the  $\alpha\beta$ -ATP-treated SCID mice (Fig. 4c, d and Supplementary Fig. 12c). Thus, ATP-induced deterioration of colitis was accompanied by an increase in the

number of  $T_H17$  cells in this T-cell-mediated colitis model, indicating the possible involvement of ATP in the generation of 'pathogenic'  $T_H17$  cells.

From our results, we propose the following scenario: commensal-bacteria-derived ATP activates  $CD70^{high}CD11c^{low}$  cells in the lamina propria to induce IL-6 and IL-23 production as well as TGF- $\beta$  activation, thereby leading to local differentiation of  $T_H17$  cells. Our findings further suggest that this mechanism commonly operates during the differentiation of both 'naturally occurring' and 'pathogenic'  $T_H17$  cells, although additional factors certainly contribute differentially to each case<sup>30</sup>. The physiological nature and role of these  $T_H17$  cells will be an interesting issue to be addressed in the context of the maintenance of intestinal mucosal homeostasis<sup>10,12</sup>. The actual involvement of P2 receptors and subsequent intracellular signalling mechanisms responsible for the generation of the local cytokine milieu inducing  $T_H17$  cells are also interesting issues for future studies. Finally, elucidating the entire picture of the regulation of the

development of intestinal regulatory T cells,  $T_H17$  cells and other types of cells by ATP and its metabolites (ADP and adenosine) will provide valuable information towards our understanding of the complex system of intestinal mucosal immunity as well as the establishment of innovative ATP-targeted approaches for treating patients with inflammatory bowel diseases.

#### METHODS SUMMARY

**Mice, cell isolation and faecal ATP measurements.** C57BL/6J mice, CB-17 SCID mice and ICR germ-free mice were purchased from CLEA Japan. Balb/c germ-free mice were maintained at the Yakuli Central Institute. *MyD88*<sup>-/-</sup>, *Trif*<sup>-/-</sup> and *Stat3*<sup>fl/fl</sup> Lck-Cre mice backcrossed eight or more generations onto C57BL/6J were used. The details of the procedures for isolation of lamina propria lymphocytes and  $CD11c^{+}$  cells are described in Methods. Faeces from individual mice were weighed and suspended in PBS. The levels of ATP in the supernatants were determined with a luciferin-luciferase assay using an ATP assay kit (TOYO Ink.).

**Intracellular cytokine staining and *in vitro* T-cell differentiation.** The details of the procedures for intracellular cytokine staining and *in vitro* differentiation of  $CD4^{+}$  T cells are described in Methods.

**rRT-PCR.** The details of the procedures and primers used for rRT-PCR are described in Methods. For all panels, bars represent the ratio of gene to *Gapdh* expression as determined by the relative quantification method ( $\Delta\Delta CT$ ) (mean  $\pm$  s.d. of triplicate determination).


**T-cell-mediated colitis model.** Naive  $CD4^{+}CD62l^{high}$  splenic T cells from Balb/c mice were intraperitoneally transferred into SCID mice ( $3 \times 10^6$  cells per mouse). The mice were then injected with  $\alpha\beta$ -ATP (1.5 mg per mouse) or medium alone every 3 days for 4 weeks. After 6 or 8 weeks, colons were analysed.

**Statistical analysis.** Differences between control and experimental groups were evaluated using Student's *t*-test.

**Full Methods** and any associated references are available in the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

Received 4 June; accepted 7 July 2008.

Published online 20 August 2008.



**Figure 4** | Treatment with ATP exacerbates experimental colitis induced by adoptive transfer of naive  $CD4^{+}$  T cells. SCID mice were transferred with naive  $CD4^{+}$  T cells on day 0, and were intraperitoneally injected with  $\alpha\beta$ -ATP (1.5 mg per mouse) or RPMI 1640 medium every 3 days for 1 month. **a**, The mean body weights of SCID mice injected with  $\alpha\beta$ -ATP or RPMI ( $n = 6$  per group) were monitored. Error bars, s.e.m. \* $P < 0.05$  versus RPMI-injected mice. **b**, Haematoxylin- and eosin-stained colon sections of SCID mice treated with  $\alpha\beta$ -ATP or RPMI. The numbers of IL-17- and IFN- $\gamma$ -producing colonic lamina propria  $CD4^{+}$  cells ( $n = 3$  per group) are shown in **c**, and representative flow cytometry plots of  $CD4^{+}$  T cells are shown in **d**. Error bars, s.d. \* $P < 0.02$ . NS, not significant. Two independent experiments were performed with similar results.

- Weaver, C. T., Hatton, R. D., Mangan, P. R. & Harrington, L. E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. *Annu. Rev. Immunol.* **25**, 821–852 (2007).
- Bettelli, E., Oukka, M. & Kuchroo, V. K.  $T_H17$  cells in the circle of immunity and autoimmunity. *Nature Immunol.* **8**, 345–350 (2007).
- Ivanov, I. I. et al. The orphan nuclear receptor ROR $\alpha$  directs the differentiation program of proinflammatory IL-17<sup>+</sup> T helper cells. *Cell* **126**, 1121–1133 (2006).
- Liang, S. C. et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. *J. Exp. Med.* **203**, 2271–2279 (2006).
- Nurieva, R. et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. *Nature* **448**, 480–483 (2007).
- Korn, T. et al. IL-21 initiates an alternative pathway to induce proinflammatory  $T_H17$  cells. *Nature* **448**, 484–487 (2007).
- Zhou, L. et al. IL-6 programs  $T_H17$  cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. *Nature Immunol.* **8**, 967–974 (2007).
- Cho, J. H. & Weaver, C. T. The genetics of inflammatory bowel disease. *Gastroenterology* **133**, 1327–1339 (2007).
- Veldhoen, M., Hockley, R. J., Atkins, C. J., Locksley, R. M. & Stockinger, B. TGF $\beta$  in the context of an inflammatory cytokine milieu supports *de novo* differentiation of IL-17-producing T cells. *Immunity* **24**, 179–189 (2006).
- Mangan, P. R. et al. Transforming growth factor- $\beta$  induces development of the  $T_H17$  lineage. *Nature* **441**, 231–234 (2006).
- Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector  $T_H17$  and regulatory T cells. *Nature* **441**, 235–238 (2006).
- Cua, D. J. & Kastelein, R. A. TGF- $\beta$ , a 'double agent' in the immune pathology war. *Nature Immunol.* **7**, 557–559 (2006).
- Chang, S. Y. et al. Colonic patches direct the cross-talk between systemic compartments and large intestine independently of innate immunity. *J. Immunol.* **180**, 1609–1618 (2008).
- Fagarasan, S. & Honjo, T. Intestinal IgA synthesis: regulation of front-line body defences. *Nature Rev. Immunol.* **3**, 63–72 (2003).
- North, R. A. Molecular physiology of P2X receptors. *Physiol. Rev.* **82**, 1013–1067 (2002).
- Schnurr, M. et al. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. *Blood* **105**, 1582–1589 (2005).
- Khakh, B. S. & North, R. A. P2X receptors as cell-surface ATP sensors in health and disease. *Nature* **442**, 527–532 (2006).
- Idzko, M. et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. *Nature Med.* **13**, 913–919 (2007).



19. Ivanova, E. P., Alexeeva, Y. V., Pham, D. K., Wright, J. P. & Nicolau, D. V. ATP level variations in heterotrophic bacteria during attachment on hydrophilic and hydrophobic surfaces. *Int. Microbiol.* **9**, 37–46 (2006).
20. Rescigno, M. *et al.* Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. *Nature Immunol.* **2**, 361–367 (2001).
21. Niess, J. H. *et al.* CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. *Science* **307**, 254–258 (2005).
22. Travis, M. A. *et al.* Loss of integrin  $\alpha$ (v) $\beta$ 6 on dendritic cells causes autoimmunity and colitis in mice. *Nature* **449**, 361–365 (2007).
23. Takeda, K. *et al.* Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. *J. Immunol.* **161**, 4652–4660 (1998).
24. Iwasaki, A. Mucosal dendritic cells. *Annu. Rev. Immunol.* **25**, 381–418 (2007).
25. Coombes, J. L. *et al.* A functionally specialized population of mucosal CD103<sup>+</sup> DCs induces Foxp3<sup>+</sup> regulatory T cells via a TGF- $\beta$  and retinoic acid-dependent mechanism. *J. Exp. Med.* **204**, 1757–1764 (2007).
26. Denning, T. L., Wang, Y. C., Patel, S. R., Williams, I. R. & Pulendran, B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. *Nature Immunol.* **8**, 1086–1094 (2007).
27. Hendriks, J. *et al.* CD27 is required for generation and long-term maintenance of T cell immunity. *Nature Immunol.* **1**, 433–440 (2000).
28. Zaba, L. C. *et al.* Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. *J. Exp. Med.* **204**, 3183–3194 (2007).
29. Leach, M. W., Bean, A. G., Mauze, S., Coffman, R. L. & Powrie, F. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RB<sup>tryp</sup> subset of CD4<sup>+</sup> T cells. *Am. J. Pathol.* **148**, 1503–1515 (1996).
30. Mazmanian, S. K., Round, J. L. & Kasper, D. L. A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature* **453**, 620–625 (2008).

**Supplementary Information** is linked to the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

**Acknowledgements** We thank A. Iwasaki and N. Tsuji for discussion, M. H. Jang, H. Ohno, H. Yamane, M. Yoshida and H. Shiomi for technical advice and reagents, and J. Borst for CD27-deficient mice. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labour and Welfare, the Osaka Foundation for the Promotion of Clinical Immunology, the Ichiro Kanehara Foundation, Sumitomo Foundation, Senri Life Science Foundation and the Naito Foundation.

**Author Contributions** K.H. conceived the research, planned experiments and analyses and wrote the paper; K.A. and J.N. largely conducted experiments; T.S. performed some of the experiments; Y.U., M.Y., M.O., H.Y., N.I. and R.E. provided key materials; and K.T. oversaw the whole project.

**Author Information** Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). Correspondence and requests for materials should be addressed to K.H. ([honda@iongene.med.osaka-u.ac.jp](mailto:honda@iongene.med.osaka-u.ac.jp)) or K.T. ([ktakeda@iongene.med.osaka-u.ac.jp](mailto:ktakeda@iongene.med.osaka-u.ac.jp)).

## METHODS

**Reagents.** ATP $\gamma$ S (A1388),  $\alpha$ -ATP (M6517) and Bz-ATP (B6396) were purchased from Sigma-Aldrich, and dissolved in phenol-red-free RPMI1640 medium. Apyrase from potato (ATPase activity: 40–200 units (U) per mg protein, A7646), suramin (S2671), TNP-ATP (T4193) and BBG (B0770) were purchased from Sigma-Aldrich, and dissolved in PBS. For *in vivo* experiments, 80 U apyrase or 250  $\mu$ g of TNP-ATP was dissolved in 300  $\mu$ l PBS and immediately injected intraperitoneally into SPF mice every 3 days for 15 days; or 1.25 mg of ATP $\gamma$ S was dissolved in phenol-red-free RPMI1640 medium and injected daily intraperitoneally or intracranially with syringes or 1,000- $\mu$ l pipette tips, respectively, into germ-free mice for 6 days. For *in vitro* experiments, ATP $\gamma$ S,  $\alpha$ -ATP and Bz-ATP were used at 5–10  $\mu$ M; suramin at 30  $\mu$ M; TNP-ATP at 10  $\mu$ M; BBG at 100 nM; and apyrase at 15 U ml $^{-1}$ . The anti-IL-6 and anti-TGF- $\beta$  antibodies were purchased from R&D Systems and used at 10  $\mu$ g ml $^{-1}$  or 25  $\mu$ g ml $^{-1}$ , respectively.

**Mice.** CB-17 SCID mice and ICR germ-free mice were purchased from CLEA Japan. Balb/c germ-free mice were maintained at the Yakult Central Institute. *Myd88* $^{-/-}$ , *Trif* $^{-/-}$  and *Stat3* $^{fl/fl}$  Lck-Cre mice were generated as described previously<sup>23,24</sup>, and backcrossed eight or more generations onto C57BL/6J. CD27-deficient mice were used with permission from J. Borst<sup>25</sup>. Unless otherwise indicated, wild-type C57BL/6J mice purchased from CLEA Japan maintained under SPF conditions were used. All experiments were performed in accordance with the Guidelines for Animal Experiments of Osaka University.

**Faecal ATP measurements.** Faeces from individual mice were collected, weighed and gently suspended in PBS containing 0.01% NaN<sub>3</sub>. After centrifugation, the supernatants were collected and passed through 0.22- $\mu$ m filters. The levels of ATP were determined with a luciferin-luciferase assay using an ATP assay kit (TOYO Ink) according to the manufacturer's instructions, except that the cell lysis step was omitted.

**Bacterial culture.** Faeces were collected from SPF mice, gently dissolved in 10 ml of serum-free RPMI medium, passed through a mesh and incubated under aerobic condition at 37 °C for 16 h. A small aliquot of the faecal suspension was transferred into 3 ml fresh medium and further incubated under aerobic conditions at 37 °C. The growth phases of these culturable intestinal aerobic commensal bacteria were monitored spectrophotometrically at 590 nm, and ATP concentrations in supernatants were measured as above. *S. typhimurium* (obtained from the Research Institute for Microbial Diseases bacterial culture collection, Osaka, Japan) was grown in the same medium, and ATP concentration was measured in the same way. The culture supernatants collected at the late exponential phase of bacterial growth were passed through 0.22- $\mu$ m filters and used as conditioned media for co-culture of CD11c $^{+}$  cells and naive CD4 $^{+}$  T cells.

**Isolation of lymphocytes.** To prepare single-cell suspensions from spleens, mesenteric lymph nodes and Peyer's patches, the collected organs were ground between glass slides, and the cells were passed through 40- $\mu$ m nylon meshes and suspended in HBSS. Splenocytes were treated with RBC lysis buffer (0.15 M NH<sub>4</sub>Cl, 1 mM KHCO<sub>3</sub>, 0.1 mM EDTA) for 5 min before suspension. Naive CD4 $^{+}$  T cells were purified from spleens using a CD4 $^{+}$ CD62L $^{+}$  T cell isolation kit II (Miltenyi Biotec; purity 95%). For isolation of lamina propria lymphocytes (see also ref. 3), intestines were opened longitudinally, washed to remove faecal content, and shaken in HBSS containing 5 mM EDTA for 20 min at 37 °C. After removal of epithelial cells and fat tissue, the intestines were cut into small pieces and incubated with RPMI1640 containing 4% fetal bovine serum (FBS), 1 mg ml $^{-1}$  collagenase type II (Invitrogen), 1 mg ml $^{-1}$  dispase (Invitrogen) and 40  $\mu$ g ml $^{-1}$  DNase I (Roche Diagnostics) for 1 h at 37 °C in a shaking water bath. The digested tissues were washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (GE Healthcare) and overlaid on 2.5 ml of 80% Percoll in a 15-ml Falcon tube. Percoll gradient separation was performed by centrifugation at 780g for 20 min at 25 °C. The lamina propria lymphocytes were collected at the interface of the Percoll gradient and washed with MACS buffer (0.5% BSA and 2 mM EDTA in PBS) or RPMI1640. The cells were used immediately for experiments.

**Isolation of lamina propria CD11c $^{+}$  cells.** Lamina propria CD11c $^{+}$  cells were isolated using a protocol modified from an EDTA perfusion method<sup>26</sup>. Mice were anesthetized and their peritoneal and pleural cavities opened. Next, 10 ml of 20 mM EDTA in HBSS was perfused through the left ventricle of the heart. At the end of the perfusion, the entire colon or small intestine excluding the caecum was removed, opened longitudinally and washed to remove faecal content. Colons were then cut into halves and placed in tubes filled with 2 mM EDTA in HBSS. The tubes were shaken at 4,800 oscillations per min for 50 s using a mini beater (Biospec Products). The tissues were washed with PBS and the epithelial cells and muscle layers removed with tweezers. In some experiments, the epithelial cell sheets were collected and kept in ice-cold HBSS until RNA extraction. After

removal of epithelial cells and muscle layers, the tissues were then cut into small pieces and incubated with RPMI1640 containing 4% FBS, 1 mg ml $^{-1}$  collagenase type II, 1 mg ml $^{-1}$  dispase and 40  $\mu$ g ml $^{-1}$  DNase I for 1 h at 37 °C in a shaking water bath. After filtration of the digested tissues through a 40- $\mu$ m cell strainer, the isolated cells were washed with MACS buffer and CD11c-positive cells were purified twice to >95% purity using CD11c MicroBeads (Miltenyi Biotec). In some experiments, enriched CD11c-positive cells were further stained with specific antibodies and sorted by FACS VantageSE (BD Biosciences), with a resulting purity of around 95%.

**Isolation of splenic CD11c $^{+}$  cells.** Spleens were collected and incubated with RPMI1640 containing 4% FBS, 1 mg ml $^{-1}$  collagenase type II, 1 mg ml $^{-1}$  dispase and 40  $\mu$ g ml $^{-1}$  DNase I for 1 h at 37 °C in a shaking water bath. After treatment with RBC lysis buffer, the isolated cells were washed with MACS buffer and CD11c-positive cells purified twice to >95% purity using CD11c MicroBeads (Miltenyi Biotec).

**Intracellular cytokine staining.** The intracellular expression of IL-17 and IFN- $\gamma$  in CD4 $^{+}$  T cells was analysed using a Cytotoxic/Cytoperm Kit Plus (with GolgiStop; BD Biosciences) according to the manufacturer's instructions. In brief, lymphocytes obtained from the intestinal lamina propria, spleens, mesenteric lymph nodes or Peyer's patches were incubated with 50 ng ml $^{-1}$  phorbol myristate acetate (PMA; Sigma), 5  $\mu$ M calcium ionophore A23187 (Sigma) and GolgiStop in complete media at 37 °C for 4 h. Surface staining was performed with a corresponding cocktail of fluorescently labelled antibodies for 20 min at 4 °C; after this, the cells were permeabilized with Cytotoxic/Cytoperm solution for 20 min at 4 °C and intracellular cytokine staining was performed with fluorescently labelled cytokine antibodies for 20 min.

**In vitro T-cell differentiation.** Naive CD4 $^{+}$  T cells were collected for 4 days with purified CD11c $^{+}$  cells and 0.5  $\mu$ g ml $^{-1}$  anti-CD3 antibody (BD Biosciences) in the presence or absence of ATP. The cultured cells were harvested and rested for 2 h before being restimulated with PMA and calcium ionophore (Sigma) for 3 h.

**Flow cytometry.** The following antibodies were used: anti-CD4-Cy5, anti-IFN- $\gamma$ -FITC, anti-IL-17-PE, anti-CD8-FITC, anti-CD11b-PE, anti-CD11b-FITC, anti-CD11c-PE, anti-CD11c-APC, anti-CD80-FITC, anti-CD103-FITC (all BD Biosciences), anti-CCR6-PE (R&D Systems Inc.), anti-F4/80-Alexa488 (Caltag Laboratories), anti-CD70-biotin (eBioscience), rabbit anti-CX3CR1 antibody (Torrey Pines Biolabs), streptavidin-Alexa488 and goat anti-rabbit IgG-Alexa488 (Molecular Probes). Data were acquired using a FACSCalibur or a FACSCanto (BD Biosciences) and analysed using Flowjo software (Tree Star).

**Real-time RT-PCR.** Complementary DNAs were synthesized from RNA samples prepared with an RNeasy Mini Kit (Qiagen) using Rever Tra Ace RT (Toyobo). Complementary DNAs were analysed by RT-PCR using Power SYBR Green PCR Master Mix (Applied Biosystems) in an ABI 7300 real time PCR system (Applied Biosystems). Serial dilutions of a standard were included for each gene to generate a standard curve and allow calculation of the input amount of cDNA for each gene. Values were then normalized by the amount of GAPDH in each sample. The primer sets were designed with Primer Express Version 3.0 (Applied Biosystems) and initially tested to confirm comparable (>90%) efficiencies. The following primer sets were used: *Il17a*, 5'-GGACTCCACCGCAATGA-3' and 5'-GGCACTGAGCTCCAGATC-3'; *Il17f*, 5'-CCCACTGGGATTCACATCAC-3' and 5'-CATTGATGCAGCTGAGTGTCT-3'; *Il21*, 5'-GGCAATGAAAGCCTGTGGAA-3' and 5'-GGCAATGAAAGCCTGTGGAA-3'; *Rorc*, 5'-GGAGGACAGGGAGCCAAAGT-3' and 5'-CGTAGTGGATCC-CAGATGACT-3'; *Ifig*, 5'-TCAAGTGGCAGATAGATGGGAAGAA-3' and 5'-TGGCTCTGCAGGATTTTCATG-3'; *Il4*, 5'-GGCATTTTGAAGCAGGTTGCA-3' and 5'-GACGTTTGGCAGCATCCATCTC-3'; *Il6*, 5'-CTGCAAGAGACTTCCATCCAGTT-3' and 5'-AAGTAGGGAAGCCCTGGTT-3'; *Ilgb8*, 5'-ACAGCATCGCATGGACAA-3' and 5'-AAGCAACCCGATCAA-GAATGTG-3'; *Ilgav*, 5'-CGCCTACTCTCGGATGAATC-3' and 5'-CCAACCGATATCCATGAAATG-3'; *Gupdh*, 5'-CCTCGTCCCGTAGA-CAAAATG-3' and 5'-TCTCCACTTGGCAGTCA-3'; *P2rx1*, 5'-ACGAAACAAGAAGGTGGGAGT-3' and 5'-AGGCCACTTGAGTCTGGTAT-3'; *P2rx2*, 5'-GAGAGCTCCATCATCAACAAA-3' and 5'-CAGGGTCTGGGAAGGAGTAAC-3'; *P2rx3*, 5'-CCGAAACTTCCATTTTCA-3' and 5'-TTTATGCTCTGCGGTGAGG-3'; *P2rx4*, 5'-TGGTACAATTCAGGTTTGC-3' and 5'-GATCATGGTGGGATGATGC-3'; *P2rx5*, 5'-AACCGTTGGACAACAACAC-3' and 5'-TTTCATCAGGTCACCGAATC-3'; *P2rx7*, 5'-CCAGGAAGCAGGAGAACTT-3' and 5'-ATCCGTTCTTGTGATCCAG-3'; *P2ry1*, 5'-GGCAGGCTCAAGAAGAAGAT-3' and 5'-TCCAGTCCAGAGTAGAAGA-3'; *P2ry2*, 5'-CCGAGAGCTTTTAGC-CATTT-3' and 5'-GCCATAAGCAGTAACAGCC-3'; *P2ry6*, 5'-CTACCTG-CATTAGCTTCCAG-3' and 5'-ACACGACTCCACACACTACC-3'; *P2ry12*, 5'-GTTCTGGGGTTGATAACCAT-3' and 5'-GCCAGATGACAACAG-AAAGA-3'; *P2ry13*, 5'-CGTTCAGGAAAACCTTTGTCA-3' and 5'-

ACACTTCTTCACGGATGATGG-3'. The *Trif*, *Ii22* and *Ii23a* primer and probe (FAM MGB Probe) were purchased from Applied Biosystems.

**ELISA for faecal IgA.** Faeces (50–100 mg) were collected from individual mice, weighed and homogenized in 100  $\mu$ l of PBS containing 0.01% NaN<sub>3</sub> per 10 mg of faeces. After centrifugation at 9,000g for 5 min, the supernatants were collected and diluted by 1:1,000. IgA levels were determined by ELISA using a mouse IgA ELISA quantitation kit (Bethyl Laboratories) and TMB solution (eBioscience). Optical densities were determined at a wavelength of 450 nm with a reference wavelength of 570 nm.

**T-cell-mediated colitis model.** Naive CD4<sup>+</sup> CD62L<sup>high</sup> splenic T cells from Balb/c mice were purified and intraperitoneally transferred into SCID mice ( $3 \times 10^5$  cells per mouse). The mice were then injected with  $\alpha\beta$ -ATP in RPMI (1.5 mg per mouse) or medium alone every 3 days for 4 weeks. After 8 weeks, the colons were examined for the numbers of IL-17- and IFN- $\gamma$ -producing CD4<sup>+</sup> cells or analysed histologically after haematoxylin and eosin staining.

31. Yamamoto, M. *et al.* Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. *Science* **301**, 640–643 (2003).
32. Mizoguchi, E. *et al.* Colonic epithelial functional phenotype varies with type and phase of experimental colitis. *Gastroenterology* **125**, 148–161 (2003).

## Blockade of CXCL12/CXCR4 Axis Ameliorates Murine Experimental Colitis

Sakae Mikami, Hiroshi Nakase, Shuji Yamamoto, Yasuhiro Takeda, Takuya Yoshino, Katsushiro Kasahara, Satoru Ueno, Norimitsu Uza, Shinya Oishi, Nobutaka Fujii, Takashi Nagasawa, and Tsutomu Chiba

Department of Gastroenterology and Hepatology, Graduate School of Medicine (S.M., H.N., S.Y., Y.T., T.Y., K.K., S.U., N.U., T.C.), Graduate School of Pharmaceutical Science (S.O., N.F.), and Department of Medical Systems Control, Institute for Frontier Medical Sciences (T.N.), Kyoto University, Kyoto, Japan

Received May 12, 2008; accepted August 19, 2008

### ABSTRACT

Recent studies indicate that the CXCL12/CXCR4 interaction is involved in several inflammatory conditions. However, it is unclear whether this interaction has a role in the pathophysiology of inflammatory bowel disease (IBD). We investigated the significance of this interaction in patients with IBD and in mice with dextran sulfate sodium (DSS)-induced colitis and the effect of a CXCR4 antagonist on experimental colitis. First, we measured CXCR4 expression on peripheral T cells in patients with IBD. Furthermore, we investigated CXCR4 expression on leukocytes and CXCL12 expression in the colonic tissue of mice with DSS-induced colitis, and we evaluated the effects of a CXCR4 antagonist on DSS-induced colitis and colonic inflammation of interleukin (IL)-10 knockout (KO) mice. Colonic inflammation was assessed both clinically and histologically. Cytokine production from mesenteric lymph node cells was also examined.

CXCR4 expression on peripheral T cells was significantly higher in patients with active ulcerative colitis (UC) compared with normal controls, and CXCR4 expression levels of UC patients correlated with disease activity. Both CXCR4 expression on leukocytes and CXCL12 expression in colonic tissue were significantly increased in mice with DSS-induced colitis. Administration of a CXCR4 antagonist ameliorated colonic inflammation in DSS-induced colitis and IL-10 KO mice. CXCR4 antagonist reduced tumor necrosis factor- $\alpha$  and interferon- $\gamma$  production from mesenteric lymph node cells, whereas it did not affect IL-10 production. The percentage of mesenteric Foxp3<sup>+</sup> CD25<sup>+</sup> T cells in DSS-induced colitis was not affected by CXCR4 antagonist. These results suggest that blockade of this chemokine axis might have potential as a therapeutic target for the treatment of IBD.

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, relapsing, and remitting condition with unknown etiology that exhibits various features of immunologic abnormality (Fiocchi, 1998;

Blumberg et al., 1999). The pathogenesis of IBD involves the interplay of environmental, genetic, microbial, and immune factors, which result in chronic intestinal inflammation. Among these factors, immune cells, including CD4<sup>+</sup> T cells, have crucial roles in the pathophysiology of IBD (Sartor, 1995). It is important to note that the expression of chemoattractive proteins (chemokines) and adhesion molecules expressed on various cells of the intestinal tissues regulate the recruitment of such inflammatory cells. Therefore, regulation of the migration of inflammatory leukocytes into the intestinal tissues is considered to be a therapeutic option for patients with IBD.

Chemokines are small cytokines exhibiting selective chemoattractive properties for targeting leukocytes. Based on

This work was supported by a grant-in-aid for Scientific Research (C) from the Ministry of Culture and Science of Japan (Grant 18590677; to H.N.); grants-in-aid for Scientific Research (16017240, 16017249, 17013051, 17659212, and 18012029) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; grant-in-aid for Scientific Research (15209024 and 18209027) from Japan Society for the Promotion of Science; and grant-in-aid for Research on Measures for Intractable Diseases, and Research on Advanced Medical Technology (nano005) from the Ministry of Health, Labor, and Welfare, Japan to Tsutomu Chiba.

Article, publication data, and citation information can be found at <http://jpet.aspetjournals.org>.  
doi:10.1124/jpet.108.141085.

**ABBREVIATIONS:** IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; DSS, dextran sulfate sodium; IL, interleukin; KO, knockout; Abs, antibodies; FACS, fluorescence-activated cell sorter; MTWIS, modified Truelove Witts severity index; GFP, green fluorescent protein; TF14016, 4-fluorobenzoyl-H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH<sub>2</sub> (S-S bridged, Nal = L-2-naphthylalanine; Cit = L-citrulline); PBS, phosphate-buffered saline; MLN, mesenteric lymph node; Gr-1, granulocyte-differentiation antigen-1; Mac-1, macrophage adhesion molecule-1;  $\alpha$ -SMA,  $\alpha$ -smooth muscle actin; PECAM-1, platelet endothelial cell adhesion molecule-1; rRNA, ribosomal RNA; TNF, tumor necrosis factor; IFN, interferon; Th, T helper.

the motif of the first two cysteines, chemokines are categorized into four major subfamilies: CC, CXC, C, and CX3C chemokines. The most important function of chemokines is their ability to regulate leukocyte recruitment, retention, and trafficking in inflamed tissues (Homey et al., 2002; Ogawa et al., 2004). The expression of several chemokines is increased in the colonic tissue of murine experimental colitis models (Andres et al., 2000; Ajuebor et al., 2004) as well as in colonic biopsy specimens from patients with IBD (Gjtsbers et al., 2006). Therefore, much attention has been directed to such chemokines as one of the therapeutic targets for patients with IBD.

CXCL12 was first characterized as pre-B cell growth stimulating factor (Nagasawa et al., 1996a) and is constitutively expressed in stromal cells within the bone marrow (Tokoyoda et al., 2004). Its primary physiologic receptor is CXCR4, which also functions as an entry receptor for strains of human immunodeficiency virus (Bleul et al., 1996). The CXCL12/CXCR4 chemokine axis has an important role in the migration of progenitors during embryonic development of the cardiovascular, hematopoietic, and central nervous systems (Nagasawa et al., 1996b; Tachibana et al., 1998; Zou et al., 1998). Thus, this chemokine axis is considered to serve as a homing beacon during differentiation.

Recent studies showed that this chemokine axis is also involved in several inflammatory diseases, including rheumatoid arthritis (Nanki et al., 2000; Tamamura et al., 2004; Haas et al., 2005), inflammatory liver diseases (Terada et al., 2003; Wald et al., 2004), uveitis (Curnow et al., 2004), and pulmonary fibrosis (Phillips et al., 2004). Nanki et al. (2000) reported that memory T cells highly express CXCR4, and the CXCL12 concentration is extremely high in the synovial fluid of patients with rheumatoid arthritis. Furthermore, Wald et al. (2004) reported that CXCL12 is up-regulated in the endothelium of neoblastic vessels of chronically inflamed liver tissues, and CXCR4<sup>+</sup> lymphocytes are increased in hepatitis C virus-infected liver tissues with chronic hepatitis. These findings suggest that the CXCL12/CXCR4 axis has an important role in cell trafficking not only in the homeostatic state but also under inflammatory conditions. However, it is not clear whether this chemokine axis is involved in the pathophysiology of IBD.

To elucidate the role of the CXCL12/CXCR4 interaction in colonic inflammation, we first investigated CXCR4 expression on peripheral T cells in patients with IBD. Next, we investigated the expression of both CXCR4 in peripheral T cells and its ligand CXCL12 in the colonic tissue in a dextran sulfate sodium (DSS)-induced colitis mouse model, and then we examined the effect of a CXCR4 antagonist on DSS-induced colitis and interleukin (IL)-10 knockout (KO) mice.

## Materials and Methods

**Human Samples of Peripheral Blood Cells.** Peripheral blood cells were obtained from the following: 17 patients (7 men, 10 women) with active UC; 9 patients (2 men, 7 women) with inactive UC; 8 patients (6 men, 2 women) with active CD; 16 patients (13 men, 3 women) with inactive CD; 6 patients (4 men, 2 women) with infectious colitis; and 5 patients (5 men) as normal controls. Lymphocytes of blood samples were separated by Lymphoprep (Axis-Shield PoC AS, Oslo, Norway). Cells were stained with appropriate fluorochrome-conjugated antibodies (Abs) and were incubated for 30 min at 4°C. Monoclonal antibody against human CD3 (UCHL1) was

obtained from eBioscience (San Diego, CA), and anti-human CXCR4 (12G5) and IgG isotype control were obtained from Dako Denmark A/S (Glostrup, Denmark). Stained cells were analyzed with a fluorescence-activated cell sorter (FACS) (Beckman Coulter, Fullerton, CA). To determine disease activity, modified Truelove Witts severity index (MTWSI) was used for patients with UC and CD activity index was used for patients with CD. UC patients who scored >4 on the MTWSI and CD patients who scored >150 on CD activity index were classified to have active disease. Informed consent was obtained from each patient, and the experimental designs of these studies were approved by the Kyoto University Hospital Ethics Committee.

**Animals.** Female C57BL/6 mice (8–10 weeks of age, weighing 17–20 g) obtained from Japan SLC Inc. (Shizuoka, Japan) and CXCL12/green fluorescent protein (GFP) knockin mice (Tokoyoda et al., 2004) were used for the experiments. They were fed with standard laboratory chow and tap water ad libitum. All mice were housed in specific pathogen-free conditions in the animal facility of Kyoto University. The studies were approved by the animal protection committee of our institution.

**Experimental Design of DSS-Induced Colitis.** For the induction of colitis, C57BL/6 mice (wild-type and CXCL12/GFP knockin mice) were given 2.5% DSS (molecular mass, 36–50 kDa; MP Bio-medicals, Irvine, CA) in their drinking water for 5 days (from day 0 to 4). On day 5, they were switched to regular drinking water. Normal control mice received regular drinking water throughout the experiment.

CXCR4 antagonist TF14016 was obtained from Prof. N. Fuji (Kyoto University, Kyoto, Japan) (Tamamura et al., 2003, 2004). One hundred micrograms of TF14016 dissolved with 200  $\mu$ l of phosphate-buffered saline (PBS) or 200  $\mu$ l of PBS alone was administered intraperitoneally once a day during the study period (from day 0 to day 10). Body weight was measured daily throughout the experiment, and mice were killed by cervical dislocation at 10 days after the start of DSS administration. The colonic tissues and mesenteric lymph nodes (MLNs) were removed from each mouse and examined as described below. At necropsy, the length from the ileocecal junction to the anal verge was measured as the colonic length.

**Microscopic Assessment of Colonic Damage.** The distal third of the colon was evaluated because this segment is most severely affected in DSS-induced colitis (Okayasu et al., 1990). The entire colon was removed, opened longitudinally, and washed with PBS. The distal third of the colon was dissected and then the longitudinal section (1.5 cm from the anal verge) was prepared. For section staining, samples were fixed in acetone and stained with hematoxylin and eosin, and histologically was analyzed in a blind manner. Histological damage was quantified by the histological scoring system described by Williams et al. (2001). In brief, the sections were graded to access inflammation severity, inflammation extent, and crypt damage. The grading index for inflammation severity was as follows: 0, none; 1, mild; 2, moderate; and 3, severe. The grading index for inflammation extent was as follows: 0, none; 1, mucosa; 2, mucosa and submucosa; and 3, transmural. The grading index for crypt damage was as follows: 0, none; 1, basal one-third damaged; 2, basal two-thirds damaged; 3, crypts lost but surface epithelium present; and 4, crypts and surface epithelium lost. Each of these grades was also scored according to the percentage of involvement (0, 0%; 1, 1–25%; 2, 26–50%; 3, 51–75%; and 4, 76–100%). Each subscore (inflammation severity score, inflammation extent score, and crypt damage score) was the product of the grade multiplied by the percentage of involvement. The total colitis score was the sum of the three subscores.

**Flow Cytometry Analysis.** For analyzing changes of CXCR4 expression on leukocytes, peripheral blood was taken by tail cutting at day 0, 3, 7, and 10 after start of DSS administration. Erythrocytes were removed using lysis buffer (0.16 M NH<sub>4</sub>Cl and 0.017 M Tris, adjusted to pH 7.2), and leukocyte population was resuspended in Dulbecco's modified Eagle's medium containing 2% fetal calf serum. Cells ( $1 \times 10^6$ ) were stained with the appropriate fluorochrome-

conjugated Abs and were incubated for 30 min at 4°C. Monoclonal Abs against granulocyte-differentiation antigen-1 (Gr-1) (RB6-8C5), macrophage adhesion molecule-1 (Mac-1) (M1/70), CXCR4, CD4 (L3T4), CD8 (Ly-2), CD25 (7D4), and rat IgG isotype control were obtained from BD Pharmingen (San Diego, CA). Regulatory T cells (Foxp3<sup>+</sup> cells) were stained with the Mouse Regulatory T cell Staining Kit (eBioscience). Stained cells were analyzed with FACSCalibur (BD Biosciences, San Jose, CA). Dead cells were excluded by propidium iodide staining. The data are presented as relative fluorescence intensity or geometric mean fluorescence intensity depicting the degree of the expression of the surface molecule on the cell.

**Immunohistochemical Staining and Confocal Microscopy.** For section staining, samples were fixed in 4% paraformaldehyde and equilibrated in 30% sucrose/PBS or fixed with acetone for 2 min. Cryostat sections of colonic tissues were stained and mounted with Permafluor (Beckman Coulter). All confocal microscopy was carried out on a LSM 510 META (Carl Zeiss Inc., Thornwood, NY). Monoclonal Abs against  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA), platelet endothelial cell adhesion molecule-1 (PECAM-1), CD4, CD8, Gr-1, Mac-1 (BD Pharmingen), and mouse IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) were used. For secondary antibodies, Alexa Fluor 546 goat anti-rat or rabbit IgG and Cy5 donkey anti-rat IgG (Jackson ImmunoResearch Laboratories Inc.) were used. Biotinylated antibodies were visualized with streptavidin-Alexa Fluor 546 (Invitrogen, Carlsbad, CA) or streptavidin-Cy5 (Jackson ImmunoResearch Laboratories Inc.).

**Isolation and Stimulation of Mesenteric Lymph Node Cells.** Mesenteric lymph nodes were collected under sterile conditions in ice-cold medium, and lymph nodes were mechanically disrupted and filtered through a cell strainer (70  $\mu$ m). Cells ( $2 \times 10^6$ /well) were incubated with immobilized anti-CD3 (5  $\mu$ g/ml, anti-mouse CD3; BD Pharmingen) in 200  $\mu$ l of culture medium for 72 h at 37°C in 5% CO<sub>2</sub> air. Cytokine levels in the supernatant of the culture medium were measured by enzyme-linked immunosorbent assay kit (eBioscience).

**Quantitative Analysis of RNA Expressions.** Samples of colonic tissue for mRNA isolation were removed from the distal third of the colon at 10 days after the start of DSS administration. Total RNA was extracted using the guanidium isothiocyanate-phenol-chloroform method. RNA (1  $\mu$ g) was reverse transcribed with MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA), and the resulting complementary DNAs (50 ng/reaction mixture) were analyzed for CXCL12 mRNA expression by real-time polymerase chain reaction using an ABI Prism 7700 sequence detection system (Applied Biosystems). The reaction mixtures were incubated for 2 min at 50°C, denatured for 10 min at 95°C, and subjected to 45 amplification cycles consisting of annealing and extension at 60°C for 1 min followed by denaturation at 95°C for 15 s. The primers and probes used for this experiment were obtained from Applied Biosystems. To quantify isolated RNA and to measure cDNA synthesis efficiency, target cDNAs were normalized to the expression levels of the endogenous reference housekeeping gene, 18S ribosomal RNA (rRNA). The oligonucleotide primers used for CXCL12 rRNA amplification and detection were 5'-CCA GAG CCA ACG TCA AGC AT-3' (forward) and 5'-CAG CCG TGC AAC AAT CTG AA-3' (reverse). The oligonucleotide primers used for 18S rRNA amplification and detection were 5'-TAGAGTGTCAAAGCAGGCC-3' (forward) and 5'-CCAACA-AATAGAACCAGCGT-3' (reverse). For simplicity, the expression level of the target gene was expressed as values relative to the control in the experiment.

**Migration Assay.** Fresh bone marrow cells and MLN cells from C57BL/6 mice were preincubated with or without 1  $\mu$ M of TF14016 for 30 min at 37°C. Then they were transferred to the upper layer of 3- or 5- $\mu$ m pore polycarbonate membrane (Transwell; Corning Inc., Corning, NY), which overlaid the lower chamber containing 100 ng/ml CXCL12. After 2 h, a fraction of the cells that migrated to the lower chamber was stained and analyzed by flow cytometry.

**Experimental Design of IL-10 KO Mice.** Fifty milligrams/mice per day of CXCR4 antagonist, TF14016, or PBS alone was administered intraperitoneally to IL-10 KO mice at 6 weeks of age. Twenty-eight days (4 weeks) after the start of treatment, TF14016 or PBS-treated mice were killed for histological analysis of colonic tissue.


**Microscopic Assessment of Chronic Damage in IL-10 KO Mice.** Mice were monitored for clinical signs of colitis, including diarrhea and weight loss. At necropsy, samples of the colon (transverse, distal, and proximal) and the rectum were collected and histopathologically examined as described previously. For each section, inflammation (macrophage, lymphocyte, and neutrophil infiltration in the lamina propria or submucosa) was scored for severity according to the following criteria: normal, 0; minimal, 1; mild, 2; moderate, 3; marked, 4; and severe, 5. Gland loss and epithelial hyperplasia were scored by percentage of area involved: none, 0; 1, 1–10% of the mucosa affected; 2, 11–25% affected; 3, 26–50% affected; 4, 51–75% affected; and 5, 76–100% affected. The summed scores for inflammation (lamina propria or submucosa), gland loss, and gland hyperplasia were then determined for each animal. One pathologist without knowledge of this study scored the sections according to standard criteria.

**Statistical Analysis.** All normalized data were represented as mean  $\pm$  S.D. In human experiments assessing CXCR4 expression on T cells, the Kruskal-Wallis test with Bonferroni/Dunn analysis was used. A linear regression analysis was used to access the quantitative relation between the intensity of CXCR4 expression on T cells and disease activity. In animal experiments, for two-group comparisons, the Student's unpaired *t* and Mann-Whitney *U* tests were used. For multiple comparisons, the Kruskal-Wallis test with Bonferroni/Dunn analysis for nonparametric analysis or two-way analysis of variance with Bonferroni/Dunn ad hoc analyses for parametric analysis was performed. A repeated analysis of variance was performed to assess the effect of TF14016 treatment on changes in body weight after an induction of DSS-induced colitis. In experiments using TF14016 treatments, because control mice showed a negligible level of inflammatory cytokine in tissue, one comparison using the unpaired *t* test was performed. Any significant interaction was detected in multiple comparisons (data not shown). A two-tailed *p* value of <0.05 was considered statistically significant. The SPSS software package for Windows (version 10; SPSS, Tokyo, Japan) was used.

## Results

**CXCR4 Expression on Peripheral T Cells Was Increased in Patients with Active UC.** First, we examined whether this chemokine axis is involved in human IBD. We investigated CXCR4 expression on peripheral T cells from patients with IBD and with acute infectious colitis compared with those from healthy controls. CXCR4 expression on peripheral T cells in patients with active UC was significantly higher than that in inactive UC and controls, whereas this expression in patients with active CD, inactive CD, inactive UC, and infectious colitis was not different from that in controls (Fig. 1a). Furthermore, there was a significant correlation between CXCR4 expression on peripheral T cells and disease activity (MTWSI) in patients with active UC (Fig. 1b).

**Cxcl12 Expression Was Increased in the Colonic Tissue of DSS-Induced Colitis Mice.** Next, we investigated the changes of CXCL12 expression in colonic tissue before and after DSS administration using CXCL12/GFP knockin mice. Confocal microscopic analysis was performed before and at 10 days after the start of DSS administration. CXCL12-expressing cells were mainly observed in the perivascular sites of the normal colonic mucosa (Fig. 2, a–d).



**Fig. 1.** CXCR4 expressions on peripheral T cells in patients with IBD. **a**, CXCR4 expression on peripheral T cells from patients with IBD and acute infectious colitis and healthy controls. Eighteen patients with active UC, 9 patients with inactive UC, 8 patients with active CD, 16 patients with inactive CD, 6 patients with infectious colitis, and 5 patients as normal controls. \*,  $p < 0.05$  compared with inactive UC and normal controls. **b**, correlation between CXCR4 expression of peripheral T cells and disease activity (MTWSI) in patients with UC.

The CXCL12-expressing cells were morphologically considered to be reticular cells adjacent to the endothelial (PECAM-1<sup>+</sup> and/or  $\alpha$ -SMA<sup>+</sup>) cells because they were negative for PECAM-1,  $\alpha$ -SMA, and other blood cell marker's staining.

At 10 days after the start of DSS administration, the number of CXCL12-expressing cells was increased in the inflamed colonic mucosa compared with normal colonic tissues (Fig. 2, e and f). Expression of CXCL12 mRNA was also significantly higher in the colonic tissue of mice with DSS-induced colitis (at 10 days after DSS administration) than that of normal mice (Fig. 2g). These results suggest that enhanced CXCL12 expression in the colonic mucosa might induce the migration of inflammatory cells into the inflamed colonic tissues of mice with DSS-induced colitis.

**CXCR4 Expression on Peripheral T Cells Is Increased in Mice with DSS-Induced Colitis.** To investigate whether the CXCL12/CXCR4 chemotactic axis is involved in DSS-induced colonic inflammation, we analyzed CXCR4 expression on peripheral blood cells from mice with

DSS-induced colitis. Serial changes in CXCR4 expression in the peripheral blood cells of these mice were evaluated by flow cytometry. FACS analysis revealed that CXCR4 expression on peripheral granulocytes (Gr-1<sup>+</sup> cells) was significantly increased at 7 days and normalized at 10 days after the start of DSS administration. CXCR4 expression on both peripheral CD4<sup>+</sup> and CD8<sup>+</sup> cells from mice with DSS-induced colitis was also significantly increased at 7 and 10 days (CD4<sup>+</sup>), and at 3, 7, and 10 days (CD8<sup>+</sup>) after the start of DSS administration, compared with the levels before DSS administration (day 0) (Fig. 2h).


**A CXCR4 Antagonist Efficiently Inhibits Leukocyte Migration to CXCL12 in Vitro.** To evaluate whether a CXCR4 antagonist, TF14016, efficiently blocks leukocyte migration toward CXCL12, we performed an in vitro leukocyte chemotaxis assay. Migration analysis showed that the CXCL12-induced chemotactic responses of bone marrow granulocytes and mesenteric CD4<sup>+</sup> as well as CD8<sup>+</sup> T cells were significantly inhibited by TF14016 (Fig. 3).

**Effect of a CXCR4 Antagonist on DSS-Induced Colitis.** To investigate whether the blockade of the CXCL12/CXCR4 chemotactic axis attenuates inflammation in DSS-induced colitis, we intraperitoneally administered a CXCR4 antagonist, TF14016, to mice with DSS-induced colitis. During DSS administration, the percentage of body weight in control mice (DSS alone) decreased. The body weight loss of mice with DSS-induced colitis treated with TF14016, however, was significantly lower than that of nontreated mice from 7 to 10 days after the start of DSS administration (Fig. 4a). There was also a significant difference in colonic length between nontreated and TF14016-treated mice with DSS-induced colitis (Fig. 4b).


In mice with DSS-induced colitis, the histologic findings demonstrated epithelial destruction, remarkable inflammatory cell infiltration with lymphoid aggregation, and submucosal edema (Fig. 5a). In contrast, in TF14016-treated mice with DSS-induced colitis, epithelial destruction and inflammatory cell infiltration, including lymphoid aggregation, were obviously reduced compared with nontreated mice (Fig. 5b). As a result, the total colitis score in TF14016-treated mice with DSS-induced colitis was significantly lower than that in the nontreated mice with DSS-induced colitis (Fig. 5c). Immunohistochemical analysis revealed that the number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and lymphocyte aggregation in the lamina propria were remarkably decreased in TF14016-treated mice with DSS-induced colitis compared with the nontreated mice with DSS-induced colitis (Fig. 6, a and b).

**Blockade of the CXCL12/CXCR4 Axis Reduces the Production of Proinflammatory Cytokines, but Not IL-10 Production, from MLN Cells in Mice with DSS-Induced Colitis.** We also measured the cytokine production from unseparated MLN cells from mice with DSS-induced colitis treated with TF14016. The production of tumor necrosis factor (TNF)- $\alpha$ , interferon (IFN)- $\gamma$ , and IL-10 from unseparated MLN cells was significantly increased in mice with DSS-induced colitis. However, TF14016 treatment significantly reduced the increased production of TNF- $\alpha$  and IFN- $\gamma$ . In contrast, TF14016 treatment had no effect on the production of IL-10 in mice with DSS-induced colitis (Fig. 7).

**Blockade of the CXCL12/CXCR4 Axis Did Not Block the Migration of Foxp3<sup>+</sup> Regulatory T Cells to MLN.** To elucidate why IL-10 production in MLN cells was not



**Fig. 2.** CXCL12 expression in the colonic tissue and serial changes in CXCR4 expression on peripheral blood cells of mice with DSS-induced colitis. a to d, colonic tissue sections from CXCL12/GFP knockin mice were stained with antibodies against PECAM-1 (blue) and  $\alpha$ -SMA (red) (b–d, magnified; b and c, vertical section; d, horizontal section). White bars indicate 20  $\mu$ m (a) and 10  $\mu$ m (b–d). e to g, the change of CXCL12 expression was analyzed in CXCL12/GFP knockin mice before (e) and 10 days after the start of DSS administration (f). g, CXCL12 mRNA expression in colonic tissues was quantified by quantitative real-time polymerase chain reaction. Results are presented as means  $\pm$  S.D. ( $n = 7$  in each group). \*,  $p < 0.05$  compared with control mice without DSS. h, Peripheral blood cells were obtained from mice with DSS-induced colitis before and 3, 7, and 10 days after the start of DSS administration. Serial changes of CXCR4 expression on peripheral granulocytes (Gr-1<sup>+</sup> cells) and T cells (CD4<sup>+</sup> and CD8<sup>+</sup> cells) were evaluated by FACS. Results are presented as means  $\pm$  S.D. ( $n = 5$  in each group). \*,  $p < 0.05$  compared with normal mice (day 0).




**Fig. 3.** TF14016 inhibits chemotactic responses to CXCL12 in vitro. CXCL12-induced chemotactic responses of bone marrow granulocytes (Gr-1<sup>+</sup> cells) and mesenteric T cells (CD4<sup>+</sup> and CD8<sup>+</sup> cells) were assessed in the presence (□) or absence (■) of TF14016. Data are expressed as percentage (% of input) of the loaded cells to the lower chamber. Results are presented as means  $\pm$  S.D. ( $n = 4$  in each group). \*,  $p < 0.05$  compared with leukocytes in the absence of TF14016.

changed by TF14016 treatment despite the decrease in the severity of colitis, we focused on the effect of TF14016 on regulatory T cells, one of MLN's IL-10-producing cells. First, we analyzed CXCR4 expression on regulatory T cells in MLN. In mice with DSS-induced colitis, CXCR4 expression on mesenteric CD4<sup>+</sup>CD25<sup>+</sup> T cells (nonregulatory T cells) was significantly elevated compared with that of normal mice. In

contrast, there was no significant difference in CXCR4 expression on mesenteric CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells between DSS-induced colitis mice and normal mice (Fig. 8a).

We then analyzed the population of Foxp3<sup>+</sup> regulatory T cells in MLN. FACS analysis revealed that although the percentage of Foxp3<sup>+</sup>CD25<sup>+</sup> regulatory T cells in MLN was significantly increased in mice with DSS-induced colitis com-






**Fig. 4.** Therapeutic effect of a CXCR4 antagonist, TF14016, on body weight changes and colonic length in mice with DSS-induced colitis. **a**, serial changes in body weight were measured daily throughout the experiment. Data are expressed as the mean percentage change from starting body weight. **b**, colonic length was measured from the ileocecal junction to the anal verge at 10 days after the start of DSS administration. ●, nontreated mice with DSS-induced colitis; ○, mice with DSS-induced colitis treated with TF14016; and ▲, normal mice without DSS. Results are presented as means  $\pm$  S.D. ( $n = 10-13$  in each group). \*,  $p < 0.05$  compared with the nontreated mice with DSS-induced colitis.

pared with normal mice, TF14016 treatment did not affect the percentage of Foxp3<sup>+</sup>CD25<sup>+</sup> regulatory T cells in mice with DSS-induced colitis (Fig. 8b).

**Effect of a CXCR4 Antagonist on IL-10 KO Mice.** All IL-10 KO mice treated with TF14016 or PBS survived throughout the study period. Histologic examination of colonic tissue from PBS-treated IL-10 KO mice demonstrated epithelial hyperplasia, crypt abscess, and severe acute and chronic cellular infiltration and lymphoid aggregation in lamina propria (Fig. 9a). In contrast, colonic inflammation and amount of lymphocyte aggregation were significantly decreased in IL-10 KO mice treated with a CXCR4 antagonist (Fig. 9b). As shown in Fig. 9c, colonic histological scores



**Fig. 5.** Histologic changes in colonic tissues of mice with DSS-induced colitis treated with TF14016. **a** and **b**, the representative histologic findings of colonic tissues of DSS-induced colitis mice treated with PBS (**a**) and TF14016 (**b**) are shown. **c**, histologic scores of mice with DSS-induced colitis treated with and without TF14016. Results are presented as means  $\pm$  S.D. ( $n = 8$  in each group). \*, lymphoid aggregation. \*,  $p < 0.05$  compared with the nontreated mice with DSS-induced colitis.

in IL-10 KO mice treated with TF14016 were significantly lower than in those treated with PBS alone.

## Discussion

The present study demonstrated that CXCR4 expressions on peripheral T cells of active UC patients were significantly higher than those of normal controls, and they were significantly correlated with disease activity. Furthermore, the expression of both CXCR4 on peripheral T cells and CXCL12 in the colonic tissue of mice with DSS-induced colitis were significantly increased compared with normal mice. More importantly, the administration of a CXCR4 antagonist decreased the severity of DSS-induced colitis and colonic inflammation of IL-10 KO mice, as assessed by clinical, histologic, and immunologic parameters. These results strongly suggest that the CXCL12/CXCR4 chemokine axis has an important role in the pathophysiology of IBD, particularly in UC, and that antagonist has a therapeutic effect on experimental colitis.

Previous reports demonstrated that CXCL12 mRNA expression ratio in biopsy specimens from the colonic mucosa of




Fig. 6. Confocal microscopic findings of colonic tissues in DSS-induced colitis mice treated with TF14016. The colon sections from mice with DSS-induced colitis treated with PBS (a) or TF14016 (b) were stained with antibody against CD4 (green) and CD8 (red). White bars indicate 100  $\mu$ m. A representative figure of five mice is shown. \*, mucosa-submucosa; \*\*, muscularis propria-aerosa.


patients with UC was significantly higher than that in patients with CD (Katsuta et al., 2000). In addition, IL-4 induces surface CXCR4 expression on human T cells, suggesting that this receptor might be associated with T helper (Th)2 cells (Jourdan et al., 1998; Annunziato et al., 1999). On the contrary, CXCR4/CXCL12 axis is associated with several inflammatory diseases such as rheumatoid arthritis, in which IL-6 and TNF- $\alpha$  are mainly involved. Our data also showed that CXCR4 expression in peripheral T cells is likely to be increased in patients with active CD compared with inactive CD, although there was no significant difference. These data may suggest that Th1 immune response is involved in CXCR4 expression. Fuss et al. (1996) reported that lamina propria CD4<sup>+</sup> T lymphocytes from UC patients produce both Th1 cytokine IFN- $\gamma$  and Th2 cytokine IL-5. Several reports showed that anti-TNF- $\alpha$  antibody administration reduced intestinal inflammation in patients with UC (Rutgeerts et al., 2005). Taken together, the immune response in acute flare of UC is very complicated because both Th1 and Th2 immune response and several proinflammatory cytokines are involved. Considering these data, Th2 immune response (IL-4 and IL-5) might augment CXCR4 expression on peripheral T cells under the condition of enhanced Th1 immune response. Accordingly, CXCR4 expression on peripheral T cells was strongly increased in active UC patients and that its expression level was proportional to the disease activity. In this regard, CXCR4 expression on peripheral T cells of patients with UC could be a good marker of their disease activity. However, further investigation will be needed to elucidate the exact mechanism of significant up-regulation of CXCR4 in UC patients compared with CD patients.

In animal models, we investigated CXCL12 expression in colonic tissues using CXCL12/GFP knockin mice because its expression was hardly observed by immunohistochemistry. In the steady state, CXCL12 expression was observed in submucosal lesions, mainly adjacent to the vascular endothelial cells. Based on their location, the majority of CXCL12-expressing cells are considered to be pericytes, mesenchymal-like cells located close to small blood vessel walls. Previous studies (Imai et al., 1999a,b; Peled et al., 1999a; Ponomaryov et al., 2000) reported that human and murine endothelial cells express CXCL12 mRNA and produce CXCL12 protein. CXCL12 is expressed on neoblood vessel endothelial cells in the portal tracts and on active lymphoid follicles, suggesting

the involvement of CXCL12 in the initial entry of cells into the liver during chronic hepatitis B and hepatitis C virus infection (Wald et al., 2004). In contrast to those previous reports, we found that endothelial cells did not express CXCL12 in colonic tissues, although the reason for the discrepant results is not known. We also revealed that CXCL12 expression in the inflamed colonic tissue of mice with DSS-induced colitis was significantly increased compared with normal mice. These data might suggest that circulating CXCR4<sup>+</sup> leukocytes are attracted to inflamed colonic tissues by the increased number of CXCL12-expressing cells at the perivascular sites.


To further clarify the role of the CXCL12/CXCR4 chemokine axis, we next observed CXCR4 expression on peripheral leukocytes in mice with DSS-induced colitis and found that CXCR4 expression on granulocytes and CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes is increased in mice with DSS-induced colitis compared with wild-type mice. Thus, it may be reasonable to speculate that those CXCR4-expressing T cells are recruited to the inflamed mucosa of DSS-induced colitis by enhanced expression of CXCL12. The fact that the CXCR4 antagonist ameliorates DSS-induced colitis may further support such possibility. Recent studies have indicated that various cytokines and growth factors, including IL-2, IL-4 (Jourdan et al., 1998), IL-6, stem cell factor (Peled et al., 1999b), vascular endothelial growth factor, basic fibroblastic growth factor, and transforming growth factor- $\beta$  (Buckley et al., 2000), can enhance CXCR4 expression on a number of cell types. In DSS-induced colitis, the production of various cytokines and growth factors are increased (Dieleman et al., 1994; Matsuura et al., 2005). Accordingly, these cytokines or growth factors might be involved in the induction of CXCR4 expression on granulocytes and T cells in DSS-induced colitis.

CXCR4 expression on T cells was significantly higher at 7 and 10 days after DSS administration than before DSS administration, whereas CXCR4 expression on granulocytes was increased only at day 7. In general, colonic inflammation induced by DSS administration is considered to be mainly caused by direct chemical injury to colonic epithelial cells and activation of resident macrophages and neutrophils (Okayasu et al., 1990; Cooper et al., 1993; Dieleman et al., 1994). However, we found little difference in the infiltration of mononuclear cells or neutrophils in colonic mucosa between mice with DSS-induced colitis and normal mice at 10 days



**Fig. 7.** The cytokine production of MLN cells from DSS-induced colitis mice treated with or without TF14016. MLN cells from mice 10 days after the start of DSS administration were cultured with immobilized anti-CD3. Supernatants were collected after 72 h, and TNF- $\alpha$  (a), IFN- $\gamma$  (b), and IL-10 (c) were tested by enzyme-linked immunosorbent assay. Results are presented as means  $\pm$  S.D. ( $n = 8$  in each group). \*,  $p < 0.05$  compared with DSS-induced colitis mice without TF14016 treatment. n.s., not significant.

after starting DSS administration (data not shown). These data suggest that granulocytes are attracted to the inflamed colonic tissue soon after DSS administration by other chemokines like CXCL8/IL-8 and CXCL10/inducible protein-10, the expressions of which are increased during the early phase of DSS-induced colitis (Murano et al., 2000; Melgar et al., 2006). On the other hand, the sustained increase of CXCR4 expression on peripheral T cells at the late phase of DSS-induced colitis, as observed in the present study, suggests that T cells are involved in sustained colonic inflammation after DSS administration in C57BL/6 mice. Melgar et al. (2006) reported that only 5-day administration of DSS induces chronic



**Fig. 8.** CXCR4 expression on mesenteric regulatory T cells and the population of mesenteric Fopx3<sup>+</sup> regulatory T cells in mice with DSS-induced colitis. a, CXCR4 expression on mesenteric CD4<sup>+</sup>CD25<sup>-</sup> and CD4<sup>+</sup>CD25<sup>+</sup> cells was analyzed before (white bar) and 10 days after starting DSS administration (black bar). b, the population of mesenteric Fopx3<sup>+</sup> regulatory T cells from TF14016-treated and the nontreated mice with DSS-induced colitis were analyzed by FACS. Results are presented as means  $\pm$  S.D. ( $n = 5$  in each group). \*,  $p < 0.05$  compared with normal mice. n.s., not significant.

inflammation of the colon in C57BL/6 mice. Taken together, the increased expression of CXCR4 on T cells might mainly contribute to the development of chronic colitis induced by DSS administration.

An important finding of our study is that blocking the CXCL12/CXCR4 chemotaxis axis significantly ameliorated DSS-induced colitis and colonic inflammation of IL-10 KO mice. Indeed, administration of a CXCR4 antagonist, TF14016, significantly reduced body weight loss of mice with DSS-induced colitis. Moreover, histologic findings revealed that the number of infiltrated lymphocytes and amount of lymphocyte aggregation in both DSS-induced colitis mice and IL-10 KO mice were significantly decreased when treated by the administration of a CXCR4 antagonist. These data strongly support an idea that the CXCL12/CXCR4 chemokine interaction has an important role in the development of experimental colitis, probably through the recruitment of CXCR4-positive lymphocytes to the inflamed colonic mucosa.

It should be noted that although the CXCR4 antagonist significantly reduced the expressions of TNF- $\alpha$  and IFN- $\gamma$ , it did not alter IL-10 production from MLN cells in mice with DSS-induced colitis, despite the amelioration of colonic inflammation. To clarify the reason for the lack of the effect of the CXCR4 antagonist on IL-10 production, we observed the effect on regulatory T cells in MLN. We first found that although CXCR4 expression on mesenteric CD4<sup>+</sup>CD25<sup>-</sup> cells




Fig. 9. Administration of a CXCR4 antagonist, TF14016, ameliorated histopathologic features in IL-10 KO mice. a and b, the representative histologic findings of proximal colon sections of IL-10 KO mice treated with PBS (a) and TN14016 (b) are shown. c, histologic scores of IL-10 KO mice treated with and without TF14016. Results are presented as means  $\pm$  S.D. ( $n = 11$  in each group). Black bars indicate 200  $\mu$ m. \*,  $p < 0.05$  compared with IL-10 KO mice treated with PBS.

was increased in DSS-induced colitis, there was no significant change in CXCR4 expression on mesenteric CD4<sup>+</sup>CD25<sup>+</sup> cells. Furthermore, although the percentage of Foxp3<sup>+</sup>CD25<sup>+</sup> cells in mice with DSS-colitis was significantly higher than normal mice, administration of the CXCR4 antagonist did not affect the percentage of Foxp3<sup>+</sup>CD25<sup>+</sup> cells. These data indicated that the lack of the effect of CXCR4 antagonist on IL-10 production seems to result from both no increase of CXCR4 expression on regulatory T cells in mice with DSS-induced colitis and no change of the percentage of regulatory T cells by the CXCR4 antagonist administration. Moreover, our data showed that the increased CXCR4 expression on CD4<sup>+</sup> T cells in mice with

colonic inflammation is mainly attributed to its increased expression on CD4<sup>+</sup>CD25<sup>+</sup> T cells. Taken together, the present data suggested that the ameliorating action of the CXCR4 antagonist on DSS-induced colitis is mainly due to its inhibitory effect on migration of CD4<sup>+</sup>CD25<sup>+</sup> T cells with increased CXCR4 expression that seem to be involved in exacerbation of intestinal inflammation in IL-10 KO mice that lack the function of regulatory T cells.

In conclusion, taken together with human and mouse studies, CXCL12/CXCR4 chemokine axis seems to be involved in the pathophysiology of IBD, especially ulcerative colitis. Considering the potent anti-inflammatory effect of the CXCR4 antagonist on experimental colitis, the CXCR4 antagonist might be one of the therapeutic options for patients with IBD. However, further clinical trials will be needed to assess this possibility.

#### Acknowledgments

We are deeply grateful to Dr. N. Nakao for the statistical support of this article.

#### References

- Ajuebor MN, Kunkel SL, and Hogaboam CM (2004) The role of CCL3/macrophage inflammatory protein-1 $\alpha$  in experimental colitis. *Eur J Pharmacol* 497:343-349.
- Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Ehan AK, Dawson T, Kuziel WA, Masada N, MacDermott RP, Podolsky DK, et al. (2000) Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1<sup>+</sup> lymphocyte-associated Th2-type immune response in the intestine. *J Immunol* 164:6303-6312.
- Antoniazio F, Cosmi L, Galli G, Beltrame C, Romagnani P, Manetti R, Romagnani S, and Maggi E (1999) Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. *J Leukoc Biol* 65:691-699.
- Bleil CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, and Springer TA (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/tfusin and blocks HIV-1 entry. *Nature* 382:829-833.
- Blumberg RS, Saubermann LJ, and Strober W (1999) Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. *Curr Opin Immunol* 11:648-656.
- Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D, et al. (2000) Persistent induction of the chemokine receptor CXCR4 by TGF- $\beta$ 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. *J Immunol* 165:3423-3429.
- Cooper HS, Marthy SN, Shah RS, and Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. *Lab Invest* 69:238-249.
- Curnow SJ, Wloka K, Faint JM, Amft N, Cheung CM, Savant V, Lord J, Akbar AN, Buckley CD, Murray PI, et al. (2004) Topical glucocorticoid therapy directly induces up-regulation of functional CXCR4 on primed T lymphocytes in the aqueous humor of patients with uveitis. *J Immunol* 172:7154-7161.
- Dieleman LA, Ridwan BU, Tenayson GS, Bengley KW, Bucy RP, and Eison CO (1994) Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. *Gastroenterology* 107:1643-1652.
- Frocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. *Gastroenterology* 115:182-205.
- Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, and Strober W (1996) Disparate CD4<sup>+</sup> lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN- $\gamma$ , whereas ulcerative colitis LP cells manifest increased secretion of IL-5. *J Immunol* 157:1261-1270.
- Gjebbers K, Geboes K, and Van Damme J (2006) Chemokines in gastrointestinal disorders. *Curr Drug Targets* 7:47-64.
- Haas CS, Martinez RJ, Atia N, Haines GK 3rd, Campbell PL, and Koch AE (2005) Chemokine receptor expression in rat adjuvant-induced arthritis. *Arthritis Rheum* 52:3718-3730.
- Honey B, Alenius H, Muller A, Sato H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Blumenthal E, et al. (1999b) Selective secretion of chemokine-mediated skin inflammation. *Nat Med* 5:157-165.
- Inai K, Kobayashi M, Wang J, Ohno Y, Hamada J, Cho Y, Imamura M, Musashi M, Kondo T, Hosokawa M, et al. (1999a) Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells. *Blood* 93:149-156.
- Inai K, Kobayashi M, Wang J, Shindou N, Yoshida H, Hamada J, Shindo M, Higashino F, Tanaka J, Asaka M, et al. (1999b) Selective secretion of chemokine-mediated skin inflammation: a possible role in homing of hematopoietic progenitor cells to bone marrow. *Br J Haematol* 106:905-911.
- Jourd'hean P, Abbal C, Narva N, Hori T, Uchiyama T, Vireddi JP, Buissonnet J, Taylor N, Pene J, and Yssel H (1998) IL-4 induces functional cell-surface expression of CXCR4 on human T cells. *J Immunol* 160:4153-4157.
- Katonta T, Liu C, Shimada K, Shobata K, Mitra P, Banerjee BP, Mori M, and Barnard